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Abstract
The ATP-binding cassette (ABC) superfamily of membrane transporters use energy derived from
ATP to eliminate a variety of exogenous and endogenous compounds from cells including anti cancer and
anti viral drugs, metals steroids, bilirubin, cAMP, cGMP, leukotrienes , prostaglandins. The multi drug
resistance associated protein family (MRP/ABBC) has been acknowledged as a major player involved in
multi drug resistance (MDR), in which cancers stop responding a wide array of structurally and
functionally unrelated chemotherapy drugs. Cancer is the second leading cause of death in adults in the
United States. Although there have been great strides made the treatment of cancers over the last 50 years,
there are still 1.5 million new cases and 0.5 million deaths a year in the US. The death rates for several
cancers including cervical cancer and stomach cancer in both men and women are a third of what they
were 40 years ago. However, for melanoma, esophageal, pancreatic and liver cancer death rates have
actually increased. There are various ongoing lines of research attempting to develop new therapies and
strategies to increases the efficacy of chemotherapy. One approach which has met with varying degrees of
success has been the manipulation of drug transporters involved in MDR. Inhibiting the MRPs and there
by reversing the MDR phenotype would allow the use of existing chemotherapy drugs and treatment
regimes at lower doses , thereby decreasing the magnitude of the side effects experienced patient
undergoing current treatment regimes. However the endogenous function of MRP1 has not been well
characterized, therefore inhibiting MRP1 may have unforeseen consequences. We there for decided to
look at an Mrp1 knock out mouse to determine any potential compensatory changes that might result from
the loss of Mrp1. Work has previously been done examining changes in the liver of the Mrp1-/- mouse,
we therefore looked at extra hepatic tissues. We discovered increased renal cytochrome P405 activity in
the Mrp1 -/- mice. Phase I P450 activity was altered in the testes as well, with a reduction of Cyp2c11
activity and an induction of Cyp17 activity. In addition to alterations in phase I activity, Mrp1-/- mice had
increased expression of the phase II conjugation enzyme sulfotransferase 1a1 in the small intestine, and a
reduced expression in the lungs. Interestingly, we fund that Mrp2 and Mrp4 expression was reduced in the
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lungs and Mrp2 was reduced in the kidneys of the Mrp1-/- mice. We also sought to determine any
modifications that may have resulted from the loss of Mrp1 in the testes. As Mrp1 is highly expressed in
the testes and is thought to be involved in maintaining steroid homeostasis by expelling excess estrogen
from the testes, we examined both testicular and serum steroid levels. We discovered that the loss of
Mrp1 leads to decreased steroid levels in both the testes and serum. There is a significant reduction of
androstenedione, estradiol, testosterone, and dehydroepiandrosterone (DHEA) in the testes of Mrp1
knockout mice. In order to resolve the mechanisms involved in the reduction of serum steroid levels we
examined testicular steroid biosynthesi pathways. We found no alterations in sulfotransferase or
glucuronosyltransferase enzyme activity. So it appears that in order to circumvent the buildup of excess
estrogen in the testes, steroid production is attenuated, resulting in lower androsteindione, testosterone,
and estradiol in the testes. The decrease in circulating testosterone is in all likelihood responsible for the
alterations seen in the kidney, ling and small intestines.

We also examined Mrp1-/- mice for alterations in drug disposition using tritiated vincristine for our
test compound. The loss of Mrp1and the resulting alteration in Mrp expression leads to significant build
up of vincristine in the kidney, small intestine, colon, and epididymis. This buildup of vincristine is
almost certainly an attempt to eliminate the vincristine and results from the variation in transporter
expression along the GI track and the kidney.

Mrp1 is also expressed in dendritic cells(DC) and considering Mrp1 and Mrp4 have been
implicated in DC function and a required for proper DC trafficking we decided to determine if either of
the transporters are required for efficient DC maturation and activation. By using the Mrp1-/- mouse
model, and a specific Mrp4 inhibitor, we determined potential role Mrp1 and Mrp4 play DC function. The
loss of either Mrp1 and/or Mrp4 hindered DC ability to produce IL12 when stimulated by LPS. If either
of the transporters are lost during maturation, upon activation by LPS, the DCs have reduced induction of
activation markers CD54, CD 80, CD86 and MHCII, as well as reduced IL12 production. As the ultimate
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test of DC function is activation of T cells, after inhibition of transporter activity during maturation, we
examined how effectively the DCs could activate T cells. Without functioning transporters, the ability
DCs to effectively activate T cells is severely crippled.
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Chapter One: Introduction
1.1 Cancer
The last 50 years have seen great advances in the detection and treatment of malignant
neoplasms and viral diseases. The development of chemotherapeutic treatments for cancer and
anti-viral drugs for viral infections have led to the increased quality of life for many patients and
complete relief of disease in others. However, cure rates for cancer are not 100%, and in patients
with advanced metastatic neoplasms, the long term outlook is far less encouraging, with five
year survival rates less than 5% in patients with advanced pancreatic cancer Other neoplasms
have a somewhat better prognosis (Table 1) (Jamel et al, 2008). As many as 50% of lung cancers
either do not respond or quit responding to chemotherapy drugs. Approximately 90% of primary
breast cancers initially respond to treatment, however 30% of patients have refractory disease
(Gonzalez-Angulo AM et al, 2007). In up to 90% of patients with metastatic diseases, treatment
failure is due to drug resistance (Longley DB & Johnston PG, 2005).

Table 1 – Five year cancer survival rates.
Cancer
Breast
Colon
Lung
Melanoma
Ovary
Prostate
Stomach
Pancreas
Bladder
Cervix

% Survival
88
64
15
91
45
98
24
05
80
72

*Adapted from Cancer Statistics, 2008
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Early diagnosis and improved treatment options have greatly increased survival, however
mortality from cancer is still ultimately do to treatment failure Treatment failure has become an
increasingly significant problem and has rendered many of the current chemotherapy regimens
ineffective. There are two potential reasons resulting in a poor response to chemotherapy: 1)
inability to get the drugs to cells at adequately high concentrations and 2) cancers cells becoming
resistant to the chemotherapy drugs via epigenetic and genetic mechanisms leading to alterations
in pharmacokinetics and increased drug efflux. In many cases, tumor cells simultaneously
develop drug resistance to several groups of structurally and functionally diverse chemotherapy
drugs.

The drugs lose their cytotoxic activity, a phenomenon termed multidrug resistance

(MDR). The two forms of MDR are intrinsic resistance, in which cells are resistant at the
beginning of treatment, and acquired resistance, in the patients experience relapse. Failure of
chemotherapy and antiviral therapy and the onset of MDR may be due to the increased
expression of drug exporters and their ability to efflux therapeutic compounds.

In the later part of the last century, several cancer cell lines were shown to over-express
certain proteins involved in the efflux of anticancer medication and were attributed to MDR. The
P-glycoprotein (P-gp), a 170 KDa membrane glycoprotein, was the first ABC transporter
discovered. P-gp conferred resistance to doxorubicin in cultured cells (Juliano and Ling, 1976,
Riordan JR et al, 1985).

Later, two doxorubincin resistant cell lines, HL60/ADR and H69AR, were examined. It
was determined that P-gp was not over-expressed in the two cell lines, although both
demonstrated an MDR phenotype, but rather a possible new class of transporter (McGrath et al
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1987, McGrath et al, 1988, Mirski et al, 1987). A 190kDa membrane protein was discovered
and subsequently in 1992, Cole et al. cloned the new protein, the source of MDR in the lung
cancer cell line and thus, multidrug resistance-associated protein 1 (MRP1) was discovered.
MRP1 belongs to the superfamily of ATP-binding cassette (ABC) transporters, which contains
12 members; 9 multi-drug resistances associated related proteins (MRPs1-9), cystic fibrosis
transmembrane conductance regulator (CFTR), and 2 sulfonylurea receptors (SUR1/2), with
functions including ion transport, cell surface receptors, and extrusion of endogenous and
exogenous compounds from cells. To date 7 rat and 8 mouse MRP orthologs have been
characterized. There are 48 ABC transporters in humans, divided into 7 subfamilies: ABCA,
ABCB, ABCC, ABCD, ABCE, ABCF and ABCG (reviewed in Haimeur et al 2004; Deeley et al
2006)

1.2 ATP-binding cassette transporters

The ABCC transporter family is divided into two groups depending on the number of
hydrophobic membrane spanning domains the transporter contains. The short transporters,
MRP4,5,8,and 9 each contain two membrane spanning domains, with 12 transmembrane
helices, while MRP1-3,6 and 7 have three membrane spanning domains(MSD) containing 17
transmembrane helices (Figure 1). In addition to the MSD, all members of the ABCC family
contain two nucleotide binding domains (NBDs) with both a Walker A and Walker B motif and
the signature C motif, LSGGQ, involved in ATP binding and hydrolysis (Walker et al, 1982,
Higgens et al, 1986,Ren et al, 2004). Energy derived from the hydrolysis of ATP is used to
actively transport substrates across the cell membrane. Transport is thought to be carried out in

3

stages: 1) substrate binding which causes a conformational change in the protein and increases
affinity of NBD1 for ATP, 2) ATP binds NBD1 and again cause a change in protein
confirmation, 3) A second ATP binds NBD2 , an additional conformational change, lower
affinity for the substrate, it is released; 4) the ADP fall of and the protein returns to its original
confirmation (Payen et al, 2005, Yang et al, 2004, Hou et al, 2003) (See figure 2).

Figure 3 . Topology of MRP proteins.
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Figure 2. ATP mediated transport
A) No substrate bound to MRP. B) Substrate binds transporter and first conformational change C) Increased ATP
affinity and ATP binds NBD1, conformational change. D) Second ATP binds NBD2, conformational change
decreased substrate affinity, and transport. F) ADPs falls off and the transporter returns to resting confirmation
(adapted from Borst P, et al, 2005).

MRP1/ABCC1 belongs to the ABCC subfamily of the ABC transporters. MRP1 can
transport glucuronide, glutathione, sulfate conjugates, organic ions and nucleotide analogues.
Physiological substrates include glutathione, GSSG, the proinflammatory agent leukotriene (C4,
D4,E4), S-glutathionyl prostaglandin, esterone 3-sulfate, dehydroepiandrosterone 3-sulphate
(DHEAS),17β-glucuronosyl estradiol, bilirubin and bile acids (Gottesman et al, 2002, Leslie et
al, 2001), chemotherapy drugs including camptothecin, colchicines, doxorubicin, daunorubicin,
etoposie, methotrexate, taxol, and vincristine,(reviewed in Gottesman et al., 2002, Schinkel &
Jonker, 2003, Haimeur et al, 2004, Deeley et al, 2005, Choudhuri & Klaassen, 2006, Ballator et
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al, 2008, Toyoda, et al, 2008, Zhou et al, 2008, Dean, 2009), antibiotics and anti-virals such as
ciprofloxacin, grepafloxacin, Saquinavir and ritonavir (Tami et al, 2000, Rodríguez-Ibáñez et al,
2003, Srinivas et al,1998 ) heavy metals such as arsenic and antimony (Chen et al, 1997), and
toxins including aflatoxin B and the vinca alkaloids (Loe et al., 1996; Leslie et al, 2001) across
cell membranes. MRP1 also transports a variety of anti HIV medications, including saquinavir
and zidovudine, and this is one mechanism by which HIV treatments become ineffective
(Srinivas et al, 1998, Jorajuria et al, 2004, Dallas et al, 2004, Eilers et al, 2008).

MRP1 is ubiquitously expressed at some level in most tissues (Cole et al 1996; Flens et al
1996). In mice, it is highly expressed in the lung, heart, kidney, testes and to a lesser extent, in
the intestine and liver (Maher et al, 2005). In humans, there is high expression in the esophagus,
intestine, lung, pancreas, heart, skin, peripheral blood monocytes, testes, blood-brain barrier,
blood-choroid plexus barrier, and very low levels in the liver (Peng et al., 1999; Flens et al, 1996,
Soontornmala1 et al, 2006).

Within the cells, MRP1 is located in the cytoplasm or the

basolateral membranes of polarized cells (Peng et al., 1999).

Although the true physiological role for MRP1 is not known, it appears to be essential for
proper immune function, dendritic cell migration and maturation and is a T cell activation
marker (Elliott et al, 2004, Lohoff et al 1998, van de Ven R et al, 2006, Randolph et al, 2001,
Robbiani et al 2000). Another possible physiological role is in steroid homeostasis, as MRP1
expression is highest in tissues that respond to or are involved in synthesis of steroids, including
the testes, ovaries and adrenal glands (Mayer et al, 2005, reviewed Klaassen, 2009).
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Also included in the ABCC subfamily is MRP2/ABCC2. This protein , originally termed
the canalicular multispecific organic anion transporter (cMOAT), was discovered in 1996 in
Eisai hyperbilirubinemic rats (EHBR) (Elferink et al 1995, Paulusma et al, 1996, Taniguchi et al,
1996), although the phenotype of idiopathic jaundice had been known in humans since 1954 and
in rats since 1985 (Dubin, 1954, Jenson et al, 1985). MRP2 transports similar substrates as
MRP1, including glucuronide, sulfate, and glutathione organic ion conjugates (Jedlitschky et al,
1997, Evers et al, 1998,Cui et al, 1999, Kamisako et al, 1999) . MRP2 also transports mono- and
bisglucuronosylbilirubin, bile salts as well as xenobiotic conjugates into bile for hepatobiliary
excretion (Trauner et al, 2003). Other endogenous substrates include leukotriene C4, 17βglucuronosyl estradiol, and esterone 3-sulfate (Cui et al, 1999). One of MRP2’s main functions is
to excrete bilirubin into the bile. Humans with a mutation in the MRP2 gene, leading to a non
functional transporter, have an inheritable disorder called Dubin-Johnson syndrome
characterized by a mild form of hyperbilirubinemea similar to the EHBR rats (Kartenbeck et al,
1996, Ronald et al, 1995). Additionally, MRP2 removes a variety of chemotherapy agents,
including anthracyclines, vinca alkaloids, cisplatin, etoposide, methotrexate, ,camptothecins, and
doxorubicin (Hooijberg et al 1999; Kawabe et al, 1999; Cui et al, 1999; Maher et al, 2005).
MRP2 is found mainly in the liver, kidney, and small intestine, but is also found in the colon,
gallbladder, and placenta. Unlike MRP1, MRP2 is located on the apical, not the basolateral side
of polarized cells where it extrudes compounds into luminal spaces (Paulusma at al, 1996).

MRP3/ABCC3, the third member, is found mainly in the liver, small intestine, colon,
adreanal, and to a lesser extent, the pancreas, kidney, lung, brain, spleen, and prostate (Kool et al
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1997; Belinsky et al, 1998; Scheffer et al, 2002). MRP3 is located on the basolateral side of the
cells and has substrate specificity like that of MRP1 and MRP2, including glucuronide and
sulfate conjugates, although it is a poor transporter of glutathione conjugates (Konig et al, 1999;
Hirohashi et al 1999). Endogenous substrates include leukotriene C4, 17β-glucuronosyl estradial,
folate, bilirubin, and DHEAS (Lee et al, 2004, Akita et al, 2002). Unlike both MRP1 and 2,
MRP3 transports taurocholate, glycocholate, and cholate in addition to mono- and
bisglucuronosylbilirubin bile salts (Zang et al, 2003, Hirohashi et al, 2000, Akita et al, 2002)
Anticancer drugs exported by MRP3 include methorexate, etoposide, and teniposide, however
unlike MRP1 and MRP2, it is a poor transporter of the vinca alkaloids and anthracyclines (Kool
et al, 1999; Zelcer et al, 2001). MRP3 also transports APAP glucuronide (Zamek-Gliszczynski et
al, 2006). In the MRP2 deficient EHBR rat, there is an induction of hepatic MRP3 and higher
blood levels of bilirubin presumably to compensate for the loss of MRP2 (Hirohashi et al, 1998).
\
MRP4/ABCC4, described in 1997 as the first of the short transporters, is ubiquitously
expressed in most tissues, particularly in the prostate, testis, ovary, intestine, lymphocytes,
pancreas and lung, and is located in either the apical or basolateral side of cells depending on the
tissue (Lee et al, 1998, Lee et al, 2000). First discovered in a T cell leukemia resistant to 9-(2phosphonyl methoxy) adenine (PMEA) and azidothymidine monophosphate (AZT), MRP4 can
also confer resistance to antiviral, nucleoside and nucleotide analogues including the anti viral
ganciclovir (Schuetz et al, 1999; Adachi et al ,2002; Chen et al, 2002; Reid et al, 2002). MRP4
is also an important transporter of cyclic AMP and GMP (Chen et al, 2001, Lee et al 2000).
Many important antiviral and anticancer drugs are nucleoside analogues, making this and other
nucleotide transporters of particular importance in humans. Additional physiological substrates
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include 17β-glucuronosyl estradiol, DHEAS, prostaglandins, thromboxane folate, and bile salts
(Chen et al, 2002, Zelcer et al, 2003, Rius et al, 2005).

MRP5/ABCC5 is expressed most in tissues, however at lower levels. Like MRP4, MRP5
transports nucleoside analogues as well as cyclic nucleotides (Reid et al, 2002 Jedlitschky et al,
2000). MRP5 also transports cAMP and cGMP, however has a 9-fold lower affinity for cAMP
than MRP4, but a 5-fold higher one for cGMP (Jedlitschky et al, 2000). Drug substrates include
PMEA, methotrexate, 5-fluorouracil, cadmium chloride, and potassium antimony (Wijinholds et
al, 2000, Rius et al 2003, McAleer et al, 1999, Pratt et al, 2005).

MRP6/ABCC6, found mainly in the liver and kidney, has low levels in various other
tissues, where it localizes to the basolateral membrane (Beck et al, 2005, Scheffer et al, 2008).
MRP6 transports aromatic cyclic compounds (Gottesmen et al., 2002), but does not transport
glutathione, glucuronide conjugates or cyclic nucleotides (Belinsky et al, 2002). It does however
transport an endothelin receptor antagonist, BQ123, a cyclopentapeptide, and leukotriene C4
(Madon et al, 2000)

MRP6 does confer low level resistance to etoposide, doxorubicin, and

cisplatin, but not to methotrexate or vinca alkaloids (Belinsky et al, 2002). MRP6 is of particular
interest in humans, as inherited mutations of the MRP6 gene lead to a degenerative connective
tissue disorder Pseudoxanthoma Elasticum (PXE), in which patients get calcification of the
elastic fibers and irregular collagen fibers of the arteries, skin, and retina leading to
cardiovascular difficulties, skin lessons, and blindness (Bergen et al, 2000, Mendelsohn et
al,1978, Yap et al, 1992, Lebwohl et al, 1993) The exact mechanism and exactly how MRP6 is
involved is unknown.
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MRP7/ABCC10 is present in many tissues, but at generally very low levels. Its highest
levels are in pancreas, liver, placenta, lung, kidney, brain, ovary, lymph nodes, spleen, white
blood cells, and colon (Hooper et al, 2001; Koa et al, 2002; Allikmets R, et al, 1996). MRP7 to
date has a much smaller range of physiological substrates as only two of the normal array of
physiological substrates are transported by MRP7, 17β-glucuronosyl estradiol and leukotriene C4
(Chen et al, 2003). The drug resistance profile, however is rather broad, and includes docetaxel,
paclitaxel, vincristine, vinblastine, etoposide, SN-38, and the nucleoside cancer drugs cytarabine
and gemcitabine (Hopper-Borge et al, 2004, Hopper-Borge et al, 2009). MRP7 also confers
resistance to the antivirals 2,3-dideoxycytidne and PMEA (Hopper-Borge et al, 2009). There are
a few caveats with MRP7: it is the only MRP able to transport the taxanes (Kruh et al, 2007), the
structure of MRP7 is like that of MRP1, 2, and 6, however its amino acid sequence is more
closely related to CFTR (Kruh et al, 2007), and HAL-E binds a peptide derived from a TMD
from MRP7 and inhibits cell lysis by natural killer cells (Wooden et al, 2005)

MRP8/ABCC11 is widely expressed, although at low levels, with the highest expression
found in liver, brain, and placenta (Cole et al, 1992, Gou et al, 2003). Like MRP4 and 5, MRP8
has only two MSDs (Bera et al, 2002). In MDCKII and in human HepG2 cells MRP8 localizes,
like MRP2, to the apical side, however in the CNS, MRP8 is the only MRP found in the axonal
processes of nerve cells (Bortfeld et al, 2005). MRP8’s physiological substrates include several
steroid conjugates, such as DHEAS, esterone–3 sulfate, 17β-glucuronosyl estradiol, leukotriene
C4, folate, the bile salts cholyglycine and cholyglycine, cAMP, and cGMP (Chen et al, 2005).
MRP8 induces resistance to 5-fluorouracil, 5-fluoro-2’-deoxyuridine, 5-fluoro-5’-deoxuridne,
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2’,3’- dideoxycytidine and PMEA (Guo et al, 2003). MRP8 has a splice variant which lacks the
second ATP binding domain (Yabuuchi et al, 2001). Additionally, there is no murine orthologue
for MRP8 (Shimizu et al, 2003).

MRP9/ABCC12 has been far less characterized than the other transporters, with even the
tissue distribution being debated. Transporter cellular localization and substrate profiles have yet
to be determined. MRP9 is over-expressed in breast cancer cells and expressed in various other
cancers including lung, prostate colon, prostate, ovarian, and pancreatic (Bera et al, 2002;
Tammur et al, 2001, Yabuuchi et al, 2001). There have been 4 additional splice variants detected
for MRP9 termed A, B, C, and D (Yabuuchi et al, 2001). Variants A, B and D lack the second
ATP binding domain (Yabuuchi et al, 2001). MRP9 is located on chromosome 16q12.1 both(
Tammur J, et al, . 2001). Due to its location on chromosome 16q12.1, it has been suggested that
a mutation in MRP9 may be involved in inherited paroxysmal kinesigenic choreoathetosis
disease (Yabuuchi et al, 2001)
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Table 2. Names, tissue localization, and sequence homology with ABCC1
Gene

Name

Tissue distribution

Amino Acid Sequence Identity

ABCC1

MRP1

Ubiquitous (low in liver)

100%

ABCC2

MRP2

Liver, kidney, intestine, brain

50%

ABCC3

MRP3

Liver, kidney, adrenals, pancreas,

58%

gut, placenta, &prostate
ABCC4

MRP4

Ubiquitous (↑ prostate ↓ liver)

41%

ABCC5

MRP5

Ubiquitous, low levels

38%

ABCC6

MRP6

Liver, kidney

46%

ABCC7

CFTR

ABCC8

SUR1

36%

ABCC9

SUR 2A/2B

35/36%

ABCC10
ABCC11

MRP7
MRP8

Ubiquitous low levels
Ubiquitous low levels

35%
33%

ABCC12

MRP9

Ubiquitous low levels, testes

36%

30%

Detoxification and elimination of lipophilic compounds from cells is accomplished in three
phases. In general, phase I enzymes add a hydroxyl group to a compound, making it slightly
more water soluble and add a conjugation site for phase II enzymes.

Phase II enzymes add organic anions such as glucuronide or sulfate, which greatly
increases its water solubility and also target the compound for active transport out of the cell by
one of the MRP transporters (Figure 4). For example, acetaminophen (APAP), a popular
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extensively used over the counter analgesic and antipyretic is initially metabolized in the liver by
several isoforms of phase I cytochrome P450’s (Mitchell et al., 1973; Potter et al., 1973). Next,
phase II enzymes either glucuronidate or sulfate APAP, which is then extruded from the cells by
either MRP3 or MRP4 (Zamek-Gliszczynski et al, 2006)

Figure 4 . Phases of xenobiotic metabolism and excretion
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1.3 Phase 1 Enzymes

Phase I metabolism is exemplified by the cytochrome P450

(CYP) group of

heme

containing enzymes, which is one of the largest in terms of the total number of members of the
superfamily, with 57 human isoforms, the sheer number of substrates, and their catalytic ability.
CYP enzymes are involved in monooxygenation and hydroxylation of a variety of xenobiotic
and endogenous substrates including, but not limited to, exogenous compounds, pharmaceuticals,
fatty acids, lipids, and endogenous hormones. Biotransformation generally makes compounds
more polar, but more importantly, it adds a good leaving group (OH) for further metabolism and
conjugation by the phase II enzymes. Usually this leads to detoxification of the compound.
However, in some cases, the compound becomes more toxic by means of bioactivation. Of the
15 P450’s found to be involved in the metabolism of xenobiotics >75% of drugs are metabolized
by members of 3 families; CYP 2D6, 2C9, and 3A4 (Guengerich, 2005, Yoshitomi et al, 2001).

1.4 Phase II Enzymes

Phase II xenobiotic metabolism generally involves bioconjugation with the tripeptide
glutathione, glucuronic acid, or a sulfate group to either a functional group (OH, COOH, NH2,
SH, CH, and halogens) on a compound or one which has been added during phase I metabolism.
Phase II conjugation has two consequences: 1) it usually inactivates the compound; and 2) the
compound becomes significantly more hydrophilic and can now more readily be removed from
the cell. This is the main mean by which cells are protected from reactive oxygen species (ROS)
and electrophiles. The compound can now be excreted via the kidneys and urine, or through the
14

liver and the feces. The three main enzymes involved in phase II metabolism are
glucuronosyltransferases (UGT), sulfotransferases (SULT), and glutathione S-transferases
(GST).

Glucuronosyltransferases mediate the addition of glucuronic acid to a phase I metabolite,
thereby making it more water soluble and available for transport and excretion (Tukey and
Strassburg, 2000). UGTs use the cofactor uridine diphospho-glucuronic acid (UDPGA) to
supply the glucuronic acid which is conjugated to the compound.

The nomenclature for UGTs is similar to that of the P450 system. There are 19 human
UGTs, arranged into 2 families UGT1 and UGT2, then divided into three subfamilies UGT1A,
UGT2A and UGT2B of which there are 9, 3, and 7 genes respectively (Nakamura et al, 2008).
The UGTs are found in numerous tissues, although mainly in the liver, kidney, bladder and the
intestine (Strassberg et al, 1997, Strassberg et al, 1997, Radominska-Pandya et al, 1999, Tukey
and Strassburg, 2000, Nakamura et al, 2008). One characteristic of glucuronidation not found
with the other phase II products, is presence of β-glucuronidase produced by intestinal flora,
which can cleave glucuronic acid, allowing for re-absorption and enterohepatic circulation. The
compound is glucuronidated in the liver and excreted in the bile to the small intestine where gut
bacteria cleave the glucuronic acid, and the compound is reabsorbed and transported to the liver
and the processes is repeated.

Sulfotransferases (SULT) catalyzes the sulfonation of a variety of exogenous and
endogenous compounds including monocyclic phenols, acetaminophen, paracetamol, DHEA,
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estrone, 17β-estradiol, thyroid hormone (T3), bile acids, androgens (Fujita et al, 1997, Fujita et
al, 1999,Yamazoe et al, 1999, and as reviewed in Lindsay et al, 2008 and Gamage et al, 2005).
There are two groups of SULTs. The membrane bound group are found in the Golgi and
catalyzes endogenous peptides and lipids, while the second group resides in the cytosol and are
the ones that catalyzes most exogenous as well as endogenous compounds. Sulfotransferases use
3’-phosphoadenosine-5’ phosphosulfate (PAPS) as a cofactor that donates the sulfonate group in
the reaction. This, like glucuronidation, this greatly increases the compound’s water solubility
and generally inactivates it as well. There are a several instances when SULTs bioactivate the
compounds making them more cytotoxic, such as polycyclic aromatic hydrocarbons (PAH),
some alcohols, and 2-nitropropane ( Gamage et al, 2006, Banoglu , 2000)

The nomenclature devised for the SULTs is like that of the UGTs and P450s. There are 4
families with 45% amino acid similarity (SULT1, SULT2, SULT4, and SULT6) (Blanchard et
al, 2004). The tissue distribution is somewhat more restricted than the UGTs, with the SULTs
mainly found in liver, gi tract, kidney, lung, platelets, placenta, adreanal gland, skin and prostate
(Lindsay et al, 2008).

The last of the phase II enzymes is the 45-55 KDa glutathione S –transferases (GST), a
super family that catalyzes the conjugation of glutathione (GSH) to electrophilic phase I
metabolites and reactive oxygen species (ROS). The importance of GSH can be discerned by the
fact that all life expresses glutathione. GSTs bring the GSH active site and the electrophille
together and also activate the sulfhydryl group, which allows a nucleophilic attack and
conjugation (Armstrong, 1997). Again, the new metabolite is very water soluble and usually
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inactivated. There are a few instances in which the GS-conjugate is more reactive than the
unmodified compound, such as dichloromethane, dibromoethane, hexachlorobutadiene, or the
reaction leads to depletion of cellular glutathione, such as those by quinines and isothiocyanates
(Hayes et al, 2005) . There are many endogenous and xenobiotics substrates for GSTs, including
benzo(a)pyrene 7,8-dihydrodiol-9,10 epoxide, DDT, atrozine, cisplatin ,acetaminophen,
adriamycin, LTC4, and prostaglandins (Hayes et al, 2005). In MRP1 mediated transport, GSH
may be,conjugated to a substrate, required to initiate transport, or may be co transported the
substrate (Moa et al, 2000, Loe et al, 1996)

There are 3 major GST families termed cytosolic, mitochondrial, and ER, which share
>40% amino acid sequence identity. The cytosolic are the major xenobiotic metabolizing and
make up ~95% of the cellular GST. The cytosolic GST are divided into 7 classes sharing ~25%
amino acid identity, which are alpha, Mu, Pi, Sigma, Omega, Theta, and Zeta (Eaton et al, 1999,
Hayes et al, 2005). The classes are further divided into subunits denoted by a number. Alpha and
Mu have 5, Theta and Omega 2, and Pi, Sigma, Zeta each have only 1 subunit, exp. GSTA15(Eaton et al, 1999, Casarett & Doull’s, 2007).

1.5 Compensatory changes in drug metabolizing enzymes

In the last 20 years there have been great strides made in the understanding of
compensatory changes in the drug metabolism, resulting from the loss of various components
within the pathway. Compensatory changes in phase I enzymes have been seen in several animal
knock out models. The loss of Pgp (Mdr1a) in mice led to an induction of Cyp3A (Schuetz et al,
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2000). In Mrp2-/- mice, hepatic expression of several Cyp450s are altered, with females having a
10-fold induction of Cyp2b13, a 2- fold induction of Cyp2b9, and males having a 2.2-fold
increase in Cyp7a1, and a 2-fold reduction in Cyp4a14 (Chu et al, 2006). The loss of a functional
nuclear receptor, leading to alterations in transcription, can also modify Cyp450 expression. In
farnesoid X receptor (FXR) knockout mice, Cyp3a11 is induced, whereas Cyp7a1 and Cyp8b1
are down regulated (Marschall et al, 2006, Wagner et al 2003). In retinoid-related orphan
receptor (RORα and RORγ) double knockout mice there is an induction of hepatic Cyp2b9,
2b10, 39a1, 4a14, 2b13, and a reduction in Cyp7b1, 2f2, and 8b1 expression (Kang et al, 2007).
The loss of either the constitutive androstane receptor (CAR) and/or the pregnane X receptor
(PXR) leads a reduction of Cyp7a in the liver (Uppal et al, 2005).

Compensatory changes are also seen in the expression of phase II enzymes. In HepG2
cells over expressing Cyp2E1, which may be induced in response to ethanol exposure, there is an
increase in α and microsomal GST levels, presumably to protect the cells from ethanol induced
oxidative stress (Mari and Cederbaum, 2001). In the CAR, PXR and CAR/PXR double knockout
mice there is a reduction of GstA2 expression and an increase in Ugt1A1 (Uppal et al, 2005). In
RORα null mice, Sult1E1 expression is induced (Wada et al, 2008). Mrp4 knockout mice have
reduced levels of hepatic Sult2a (Mahfoud et al, 2004). In mice with a nonfunctional cystic
fibrosis transmembrane receptor (CFTR)/ABCC7, there is increased Sult1E1 activity and mRNA
expression (Falany et al, 2002, Falany et al, 2009).

Compensatory transporter induction has also been well documented. As mentioned
previously, compensation was first shown in the Eisai hyperbilirubinemic rats (EHBR) and

18

Groningen Yellow/transporter- deficient rat (TR-), in which Mrp3 and Pgp are induced in the
liver, and Mrp4 and Pgp is induced in the kidneys, shifting the excretion of bilirubin from
hepatic to renal (Elferink et al 1995, Jensen et al, 1985, Paulusma et al, 1996, Taniguchi et al,
1996 Chen et al, 2005). There is somewhat contradictory data in Mrp2-/- mice. Chu and colleges
established induction of Mrp4 in the kidney, however they did not see an induction of Mrp3 in
the liver, while Nezases and colleges saw a reduction of hepatic Mrp3 (Chu et al., 2006, Nezasa
et al, 2006). In addition, Vlaming and colleges determined there was a 2-fold increases in liver
Mrp3 and in kidney Mrp4, in Mrp2-/- mice , they did however use a different strain of mouse
than the above two laboratories (Vlaming et al, 2006). In Fxr-/- mice, in response to bile acid
loading, there is increased expression of hepatic and intestinal Mrp3 and Mrp4, and renal Mrp4
(Zollner et al, 2003, Wagner et al, 2003, Marschall et al, 2006). Administration of carbon
tetrachloride (CCL4) to mice leads to an induction of Mrp4 and a reduction in Oatp1a1 and 1a4
in the liver, presumably to prevent accumulation of toxic metabolites (Aleksunes et al 2006,
Aleksunes et al, 2008). Compensatory induction of efflux transporters may be the result chemical
exposure or in response to loss of a functional transporter or transporters.

Pascussi and colleagues, 2008 endeavored to provide a concise review of the complexities
involved in the cross talk between nuclear receptors regulating xenobiotic metabolizing enzymes
(Table 3). It also sheds light on possible mechanisms involved in compensation, particularly in
the nuclear receptor knockout models.

Table 3. Transcriptional regulation of multi-drug resistance associated proteins. (Adapted
Urquhart et al, 2007; Qadri et al, 2009: Okada et al, 2009; Scotto, 2003)

19

Gene

Transcription Factors

Mrp1

PXR, Sp1, p53, Ap1?

Mrp2

PXR, CAR, FXR, RXR, HNF1, HNF4, Nrf2, Sp1? Ap1?

Mrp3

PXR, LXR?,CAR?, Nrf2, Sp1

Mrp4

PXR,FXR, Nrf2

In contrast to nuclear receptor induction of the transporter expression, during LPS induced
inflammatory cholestasis and the resulting released cytokines, there is a decrease in both hepatic
Mrp2 and Mrp3 expression (Hartmann et al, 2002). As mentioned above transporter regulation is
a complex network of mechanisms and much still remains to be discerned.

1.6 MRP1 transport of steroid hormones and steroid metabolism

Although MRP1 is expressed in most tissues, high expression is seen in tissues involved in
steroid hormone metabolism, such as the testes, ovaries, prostate, and adrenal glands (Bart et al,
2004, Maher et al, 2005, Nishimura et al, 2005). Also given MRP1’s ability to transport several
steroid conjugates, such as esterone 3-sulfate, with high affinity, as well as 17β-glucuronosyl
estradiol, and DHEAS, MRP1 may play a role in steroid homeostasis (Qian et al, 2001,
Jedlitscky et al, 1996, Zelcer et al, 2003). In addition to MRP1, MRP4 is widely distributed, but
at a low levels in most tissues. Expression is highest in the kidney, however expression is also
high in the prostate and testes (sertoli and leydig cells) compared to the remaining tissues (Ho et
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al, 2008, Augustine et al, 2005). Like MRP1, MRP4 transports DHEAS with high affinity and
17β-glucuronosyl estradiol (Chen et al, 2001, Zelcer et al, 2003).

Figure5. Testicular Steroid Synthesis.

Steroid synthesis in the testes begins with side chain cleavage of cholesterol to form
pregnenolone. Synthesis can then follow one of two paths: the ∆4 pathway forms progesterone,
while the ∆5 pathway forms 17hydroxypregnalone (Fig.5). ∆5 products can shift to the

4

pathway via 3 -hydroxysteroid dehydrogenase. The ultimate product in both pathways in the
testes is estradiol. However, excessive build up of estrogens in the testes can damage developing
spermatozoa (Flen et al, 1996, Wijnholds et al, 1998., Reviewed Leslie et al, 2001). With high
expression of MRP1 in the testes, and expression of Sult1E1 also in the testes, and high affinity
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for esterone 3-sulfate, MRP1 may play a role in protecting developing spermatozoa from the
feminizing effects of elevated testicular estrogen.

With respect to Mrp4s tissue distribution and substrate profile, it may contribute to
DHEA/DHEAS homeostasis. Given DHEAS is converted to DHT in the prostate, and Mrp4
transports DHEAS with high affinity and has high expression in the prostate, Mrp4 may be
involved in the regulation DHT, by adjusting the amount of available DHEA

(Zelecer et al,

2003).

1.7 Dendritic Cells

Dendritic cells (DCs), sentinels of the immune system, are potent antigen processing and
presenting cells (APCs). DCs are bone marrow derived mononuclear cells which, are MHC class
II positive and are the only cells with the ability to stimulate naïve T cells (Heath & Carbone,
2009). DCs are found throughout the body in all tissues, especially where there is an interface
between the body and the environment. There are four major types of DCs:

langerhans,

interstitial myleod derived (MDCs), monocyte-derived, and plasmacytoid-derived (PDCs). DCs
possess a heterogeneous haemopoietic lieneage, different types have been shown to display a
differential morphology, phenotype and function (Kamath A.T., et al, 2000, Kamath AT, et al
2002, Heath WR & Carbone FR, 2009). All subsets share the ability to stimulate naïve T cells
and induce proliferation.
It has been suggested that the so-called myeloid derived DCs have a stimulatory function
and lymphoid-derived have tolerogenic function, however, this idea has recently come under
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scrutiny (McLellan AD,et al, 2000, Navak N et al, 2008) Tolerance for self antigens is an
important process,so for the body will not to mount an immune response against itself. Tolerance
involves loss of proliferation of T cells after stimulation with a self antigen and the creation of
regulatory T cells, which suppress the immune response.
DC precursors travel via the bloodstream to peripheral tissues where they differentiate into
the immature DCs and can begin taking up antigens, processing and presenting them by the
major histocompatibility complex (MHC)(Rodriguez et al, 1995, Sallusto et al 1994 Sallusto et
al, 1995).

DCs play a critical role in the adaptive immune system. They are the key antigen
presenting cells (APC) of peptides to T and B cells. DCs process and present both endogenous
and exogenous antigens. DCs are the only APC capable of stimulation naïve T cells.Immature
DCs processes both intracellular antigens produced from intercellular bacteria, parasites and
viruses inside of the DC and extracellular antigens including bacteria, viruses, proteins, and
cellular debris which are internalized via pahgocytosis, pinocytosis, or endocytosis (Rodriguez et
al, 1995, Sallusto et al 1994 Sallusto et al, 1995). Larger protein antigens are processed, broken
down into peptides, and loaded onto MHC I or II molecules and transported to the cell surface
for presentation to antigen specific T cell (Mellman et al, 1998). Intracellular proteins are
degraded, loaded onto MHCI in the E.R. and the MHCI-peptide complex is transported to the
cell surface via the golgi for presentation to CD8 cytotoxic T cells (CTC) (Mellman et al, 1998).
Extracellular proteins are degraded in endosome-lysosomes to peptides, which are then loaded
on to MCH II. The MCHII is then transported to the cell surface for presentation to CD4 Helper
T cells (Th) (Sallusto et al 1994 Sallusto et al, 1995).
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DCs in the peripheral tissue express high levels of intercellular MHCII and CD1a, are
proficient antigen phagocytes, can rapidly respond to stimuli, and express little adhesion and
costimulatry molecules (CD40, CD54, CD58, CD80 and CD86).

Maturation is occurring as antigens are being processed for presentation on one of the
MCH molecules. During maturation, DCs go from being poor stimulatory cells to those with
decreased phagocytic ability. They gain motility, and begin migration from peripheral tissues to
lymphoid tissues, begin to express makers such as CD83, and, have an increased ability to
stimulate T cells (Banchereau et al, 1998). . Maturation beings when the DC is stimulated by
host inflammatory molecules such as CD40L, TNF-α, IL-1, IL-6, and IFN-α. Maturation can also
be stimulated by foreign products including LPS from gram – bacterial cell walls. These foreign
antigens are recognized by toll like receptors (TLR).

TLR recognize different types of

molecules, TRL2 responds to gram positive and TLR4 to gram negative cell wall, TLR5 respond
to flagellin, and TLR9 to CpG motifs (Guermonprez et al, 2002) Upon recognition of an antigen
by a TLR, DC maturation is initiated by a intricate signaling cascade.
As DCs mature, there is an increase in the expression of adhesion and costimulatory
molecules involved in DC –T cell interactions. Molecules that are up-regulated include CD40,
CD54, CD58, CD80, CD86 as well as MCH I and II. There is also increased excretion, of IL12,
IL10 or IFN in response to bacterial or viral infection (Guermonprez et al, 2002).

Upon maturation there are also altered changes in chemokines and chemokine receptors.
Expression of CCR1 CCR2, CCR5, and CCR6 DCs allow immature DCs to move to the site of
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infection.

After DCs have acquired antigen and begin maturing, here is a down-regulation

ofCCr1, CCR2 CCR5, and CCR6, and an up regulation of CC7 (Sallusto and Lanzavecchia,
2000). This allows DCs to migrate from peripheral tissues to lymph nodes or the spleen in
response to chemokines CCL19 and CCL 21, and leukotrienes (reviewed in Lanzavecchia et al,
20010; Randolph et al, 2005 ) . Mature DCs also secrete TARC, MDC, IP-10, RANTES, MIP1α, and MIP1β to recruit T cells and monocytes ( Sallusto and Lanzavecchia, 2000).

Once matured DCs move to lymph nodes, they interact with, and present antigen to T cells.
Interaction with T cell receptor (TCR) and CD40L lead to survival of the DC ( Caux et al, 1994).
Once in the lymph node, DCs can interact with hundreds of T cells. The DC presenting antigens
will eventually form a DC-T cell interaction, priming the T cells. This is a three step process;
first there is a quick interaction with many T cells, next a long interaction inducing activation
markers and cytokine secretion, lastly DC-T cells separate, the T cells migrate and proliferate
and leave the lymph nodes (Kleijmeer et al, 1995). In order for T cells to proliferate and become
cytokine –secreting cells, called effector cells, there must be sufficient priming by the DC
(Lanzavecchia and Sallusto, 2001). Effective priming needs a mature DC, sufficiently long DC-T
cell interaction, and high affinity of the TCR for the MHC. Proper T cell priming by the DC is
necessary for long term T cell survival, as well as differentiation into effector and memory cells
(Kleijmeer et al, 1995). If there is effective priming, T helper cells can differentiate in two
directions as either Th1 cells that produce IFNγ and aid cytotoxic T cells, or Th2 cells that
secrete IL-4, IL-5, and IL-3 in support of humeral immunity (Rissoan et al, 1999). The path the
Th cells take is dependent on the cytokines the DC is secreting. If the DC is releasing IL-2,IL-18,
and IL-27, the cells become Th1; if the DC is secreting CCL17 or CCL22 ,or there is no IL-12,
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the cells move to become Th2 (Rissoan et al, 1999). The determining factor as to which cytokine
a DC will secrete is dependent on which antigen the DC is interacting with In order for cytotoxic
T cell (CD8/CTL) response there must be a DC-CD4 Th interaction between CD40-CD40L.

In conclusion, DC’s are the most potent APC, and the only cells able to activate naïve T
cells. DC antigen aquistion and presentation is required for proper T cell stimulation leading to
activation of and long term survival of CD4 and CD 8 T cells (as reviewed by Kindt et al, 2007,
Adams et al, 2005, Janeway et al, 2001).
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Chapter two: The Loss of Multidrug Resistance Associated Protein one Leads
to Alterations in Phase I, Phase II, and Phase III Metabolizing Enzymes
Expression and Drug Disposition

Abstract:
The multidrug resistance-associated protein-1 (MRP1/ABCC1) is a 190kDa membrane-bound
glycoprotein that mediates cellular efflux of a variety of xenobiotics, typically as glucuronide,
sulfate, or glutathione conjugates. We examined alterations in phase I, II, and III detoxification
protein activity or gene expression in the kidney, lungs, and small intestine between FVB mice
and mice that lacked the multidrug resistance associated protein 1 (FVB/mrp1-/-) mice. In the
kidney, 16ά-OH (Cyp2b9, 2c11), 7ά/15β-OH (Cyp 1a1/2 & 2a1),and

16β-OH (Cyp2b1),

hydroxylation was significantly upregulated 1.53-fold, 1.48-fold and 1.18-fold respectively.
Significant changes in phase II metabolizing enzyme expression included a 2.3-fold increase in
sulfotransferase 1a1 mRNA levels in the small intestine and 1.2-fold reduction of Sult1a1 mRNA
levels in the lung. No changes were detected in sulfotransferase 1a2 or glucuronosyltransferase
expression in the FVB/mrp1-/- mice. Mrp4 expression was reduced in the lungs, andMrp2
expression was decreased in the kidney of Mrp1 knock out mice. To determine the impact of the
compensatory changes FVB/Mrp1 -/- mice were dosed with [3H] vincristine and its localization
into the organs was examined. FVB/Mrp1-/- mice have increased accumulation of vincristine in
the kidney, small intestine, colon, and epididymis. All of the enzymes differentially expressed in
the Mrp1-/- mice have some degree gender predominance. Thus changes in the expression are
presumably due to alterations in circulating serum steroid levels seen in the FVB/Mrp1-/- mice.
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However, the changes do not appear to alter drug disposition in the lungs or small intestine, but
may contribute to increased retention of vincristine in the kidney.

2.1 Introduction

The efflux of various endobiotics and xenobiotics is due in part to members of the ABCC
subfamily of ATP-binding cassette (ABC) transporters, which contains 13 genes, with functions
ranging from ion transport, cell surface receptors, and toxin ( Kruh et al 2001) (reviewed in
Haimeur et al, 2004 Wang et al 2008 ,Toyoda et al, 2008,Stanly et al, 2009). One member, the
multidrug resistance associated protein 1 (MRP1) transports glucuronide, glutathione, sulfate
conjugates, and nucleotide analogues, leukotriene C4, chemotherapy drugs like doxorubicin,
colchicines, (Jedlitschky et al. , 1996) (Gottesman et al., 2002) (Leslie et al, 2001A), heavy
metals such as arsenic and antimony (Leslie et al, 2001B), and toxins including aflatoxin B , the
vinca alkaloids, 4-(methyllnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) a tobacco metabolite
and methoxychlor (Loe et al., 1997;Leslie et al, 2001B;Tribull et al, 2003)

across cell

membranes. MRP1 is expressed ubiquitously in most tissues on the basolateral side of polarized
cells; however it is at very low expression levels in the liver (Peng et al. 1999).

Other members of the ABCC subfamily include MRP2 which is found mainly in the
liver, kidney, and intestine and unlike MRP1, it is located on the apical side, rather than the
basolateral side of polarized cells (Paulsma et al, 1996). MRP3 is found mainly in the liver,
pancreas, kidney and intestine (Cherrington et al., 2002; Belinsky et al., 1998; Kool et al., 1997),
and like MRP1, is located on the basolateral side of the cells. All three transporters have
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overlapping substrate specificities. MRP4 is ubiquitously expressed in tissues, particularly in the
prostate, testis, ovary, intestine, and lung, and is on the apical side of cells (Lee et al., 1998)
(Kruh et al., 2001). It is an important transporter of not only organic acids but also nucleoside
analogues such as PMEA, an anti-HIV nucleotide analogue, and cyclic nucleosides such as
cyclic AMP (Schuetz et al., 1999) (Kruh et al., 2001). MRP5 is expressed in most tissues and
like MRP4 transports nucleoside analogues as well as cyclic nucleotides including cAMP and
cGMP (Jedlitschky et al., 2000).

The expression of MRP transporters is also inducible by a variety of drugs and toxins
(Schrenk et al., 2001). For example, both MRP1 and MRP3 are inducible via nonsteroidal antiinflammatory drugs (NSAIDs) such as aspirin or ibuprofen in human colon cancer cells (Tatebe
et al., 2002). It has also been shown that transporters like MRP1 can be upregulated in response
to endotoxin-induced cholestasis and during other types of hepatobiliary organic ion transport
impairment (Vos et al., 1998; Tatebe et al., 2002).

There are naturally occurring models demonstrating compensatory mechanisms to
balance the loss of an ABCC transporter. Eisai hyperbilirubinemic rats and Groningen Yellow
transport deficient rat (TR--),which have an inherited nonfunctional Mrp2, appear to compensate
by inducing hepatic Mrp3 and renal Mrp4 (Ogawa et al., 2000; Akita et al., 2001, Jansen et al,
1985, Paulusma et al, 1996). The increase in Mrp3 expression diverts the elimination of bilirubin
from the liver via Mrp2,; to the kidney via Mrp3. Rats with a nonfunctional Mrp2 also have
increased expression of Mrp4 in the kidney (Chen et al., 2005). There is conflicting data in mice
lacking Mrp2 (Mrp2-/-). One group did not show induction of Mrp3 in the liver, however there
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was an increase in hepatic and renal Mrp4 (Chu et al., 2006), A second group demonstrated a
modest ~60% induction of Mrp3 in the same knock out mouse strain (C57BL/6) (Nezasa et al,
2006). A third group using a different stain of Mrp2-/- mice demonstrated a 2 fold increases in
hepatic Mrp3 and renal Mrp4, similar to the changes seen in the rat models (Vlaming et al,
2006). Mice lacking Mrp1 or Mrp3 show no obvious changes in phenotype, save a decrease in
leukotriene-induced inflammatory response in Mrp1 -/- mice (Wijnholds et al., 1997; Zelcer et
al, 2006).

Prior to transport by the MRP family, endogenous and exogenous compounds typically
need to go through several detoxification steps to both increase their water solubility and alter
their structure such that they become substrates for the transporters. In the first step, or phase I
metabolism, the compound undergoes monooxygenation and hydroxylation, which is often
mediated by the cytochrome P450 (CYP) enzymes.

These enzymes are involved in the

metabolism of a variety of xenobiotic and endogenous substrates such as carcinogens, drugs, and
steroids (reviewed in Danielson 2002). The second step, or phase II metabolism, is mediated by
enzymes such as glutathione S-transferases (GST), glucuronosyltransferases (UGT), and
sulfotransferases. These enzymes attach either a glycoprotein, sugar or sulfate respectively, to
phase I metabolites. This vastly increases the compounds water solubility and in most cases leads
to inactivation of the compound. Phase II enzymes may also be induced by various exogenous
and endogenous substrates (Reviewed Xu et al, 2005).

As with induction of different transporters to compensate for the loss of another
transporter, compensatory induction phase I and phase II enzymes due to loss of an ABC
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transporter has also been demonstrated. For example, there is induction of Cyp3a in mice
lacking P-glycoprotein (Schuetz et al., 2000). Induction of glutathione has also been shown in
mice lacking ABCC transporters, as there were increased levels of glutathione in the lung, heart,
kidney, muscle, colon, and testes in Mrp1-/- mice as compared to the wild-type mice (Lorico et
al., 1997). There is a 3.5 and 5.5 fold increase in Ugt1a expression in Mrp2 deficient TR- rats
(Johnson et al, 2006).

Previous work in our laboratory has shown FVB/mrp1-/- mice have increased expression
of hepatic Mrp2 and Mrp5 mRNA, as well as a decrease in hepatic activity of sulfotransferases
and an increase glucuronosyltransferases activity (Bain et al 2003). Thus, we decided to examine
extrahepatic tissues, including the kidneys, lungs, and small intestine to determine if there were
also changes in the expression of phase I, II and III enzymes in response to the loss of Mrp1.

2.2 Materials and Methods:

2.2.1 Collection of tissues from FVB and FVB/mrp1 -/- mice
Eight FVB and FVB/mrp -/- mice were purchased from Taconic Farms (Germantown, NY) at
five weeks of age, kept at 25o C and 50% humidity, and provided water and food ad libitum. At
nine weeks of age, the mice were euthanized with a CO2 overdose.

The lung, intestine, and

kidneys were divided into 2 sections: One placed into TRI–Reagent (Sigma Chemical Company,
St. Louis, MO) and stored at –80o C for extraction of total RNA and the other frozen at –80oC for
cytosol and microsome preparation.
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2.2.2 Testosterone hydroxylation assay
Phase I activity was measured by the testosterone hydroxylation assay (Baldwin and LeBlanc,
1992). The P450’s regio- and steriospecifically hydroxylate testosterone, so one can use this
assay to measure multiple P450’s at the same time. Individual tissues were homogenized in
cytosol buffer (10mM HEPES, pH 7.4, 1mM EDTA, 10% glycerol, 2µg/mL each of aprotinin,
leupeptin, and pepstatin)

Microsomes were separated and collected by differential

centrifugation, first at 10,000xg/ 10 min, transferring the supernatant, and again at 100,000xg/ 60
min. The supernatant containing the cytosol was stored at –80oC. The pellet containing the
microsomes was centrifuged again at 100,000xg/ 60 min and then suspended in microsome
buffer (0.1M potassium phosphate, 0.1mM EDTA, 20% glycerol at pH7.4) and stored at –80oC.
The Bradford assay was done to determine protein concentrations (Bradford, 1976).

Microsomal protein (100-200 g) was incubated in 0.1M phosphate buffer (pH7.4) with 40nmol
[14C] testosterone (53.6mCi/mmol; New England Nuclear, Boston, MA) (Baldwin and LeBlanc,
1992). Subsequently 1mM NADPH was added and incubated for 10 min at 37oC in a shaking
water bath. To terminate the reaction, 2mL ethyl acetate was added, the samples vortexed, and
then centrifuged at 1,000xg /5min. The aqueous layer was transferred to a new tube and 2mL of
ethyl acetate is added, vortexed, and the samples again were spun at 1000xg/ 5min. The 2 ethyl
acetate extracts containing the hydroxytestosterone products were combined. The samples were
evaporated under nitrogen, resuspended in ethyl acetate, and spotted on a thin layer
chromatography (TLC) plates. The plates were subsequently developed in 80% methylene
chloride/20% acetone and dried. Next they were developed in 70% chloroform/17.5% ethyl
acetate/12.5% ethanol, and then exposed to autoradiography film. Using the film as a template,
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the metabolites were cut from the TLC plate and quantitated by liquid scintillation. Activity was
measured by pmol of metabolite produced /min/mg microsomal protein. Student’s t-test was
used to determine statistical significance in phase I activity between the wild type and Mrp1 (-/-)
mice.

2.2.3 QPCR
Tissue samples were homogenized in Tri Reagent to recover total RNA, treated with RNase free
DNase. and their concentration determined by spectrophotometry. cDNA was prepared from 2µg
RNA using MMLV buffer, 400µM dNTPs, 100ng of random hexamers, 10ng of Rnasin, and 1U
MMLV-RT, and incubated at 37oC for 1 hour. The cDNA was stored at –20oC until used for
PCR. A standard was prepared for each gene to be analyzed using PCR. Briefly, 400 M genespecific primers (Table 1) were incubated with 100ng cDNA, 400µM dNTPs, and

unit Taq

polymerase,. The gene is amplified in a thermocyler, using a gene-specific annealing step (Table
1), for 40 cycles. The PCR product was purified using the Qiagen PCR purification kit (Qiagen,
Valencia, CA). The concentration of the purified sample of DNA for use in the standard curve
was determined by spectrophotometry.

QPCR was run for each of the transporters and18S RNA as a housekeeper, using Sybr Green.
Serial dilutions were made with the DNA standard and run in triplicate using real time PCR to
determine the number of RNA molecules for each gene examined. This was normalized to 18S
concentrations, and Student’s t-test was used to determine significant expression differences
between the wild type and the Mrp1 -/- mice.
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2.2.4 Alterations in vincristine disposition
FVB and FVB/mrp1-/- mice (n=3) were injected IP with 1mg/kg of [3H] vincristine sulfate (5.3
Ci/mmol) (American Radiolabeled Chemicals, St. Louis, MO). Twelve hours post injection mice
were euthanized by CO2 overdose, and the kidney, small intestine, lung epididymis liver,
gallbladder, heart, lung, stomach, spleen brain colon and testes were removed, weighed, and a
portion homogenized in 2% BSA in PBS. [3H] vincristine disposition was determined for each
organ by scintillation counting. Data is expressed as average ng vincristine/g tissue + standard
deviation, statistical differences (*) as determined by student’s t-test (p<0.05)

2.2.5 Statistical Analysis:
Was performed using Prism GraphPad software (La Jolla, CA). Statistical differences of (p<
0.05) were considered significant.

2.3 Results
2.3.1 Phase I activity is changed in a compensatory manner between FVB and FVB/Mrp1 /- mice:
Cytochrome P450s regio- and stereo-specifically hydroxylate testosterone, so this assay was used
to determine changes in phase I enzyme activity between FVB and FVB/Mrp1-/- mice, . While
there were no changes in phase I activity in the lung,.16ά-OH (Cyp2b9, 2c11), 7ά/15β-OH (Cyp
1a1/2 & 2a1), 16β-OH (Cyp2b1), and metabolite A formation was increased 1.53 fold, 1.4834

fold,1.18-fold and 1.94-fold, respectively, in the kidney of mice lacking mrp1 (Table 2). We
hypothesize that these changes in phase I activity are in response to the loss of Mrp1 and may
lead to changes in phase II and phase III interaction. Protein was extracted from the small
intestine and quantified, we unable to resolve any usable data.

2.3.2 Phase II enzyme expression is changed in a compensatory manner between FVB and
FVB/Mrp1 –/- mice:
Ugt and Sult mRNA levels were examined in the kidneys, lung, and the small intestine by realtime PCR. There were no significant changes in the expression of any of the Ugts (Figure 1).
Additionally, Ugt1a1 levels were below the detection limit in the small intestine. Sult 1a1 was
induced 2.34 fold in the small intestine , and reduced 1.22 fold in the lung of mice lacking Mrp1
(Figure 2A), while no changes were detected in Sult 1a2 (Figure 2B).

2.3.3 Phase III transporter mRNA expression in FVB and FVB mrp1-/- mice
Considering the large overlap in substrates among the ABCC transporters, we expected there to
be an induction of several of the remaining Mrps in the Mrp1-/- mice. Since Mrp1 is expressed at
relatively low levels in the liver, extrahepatic tissues such as the kidney, lung, and small intestine
were examined for compensatory changes. mRNA levels of Mrp2, Mrp3, Mrp4, and Mrp5 were
determined by real time PCR. In contrast to the liver, the only significant changes detected were
a 1.8 fold a decrease of Mrp2 in the kidney and a 1.3 fold reduction of Mrp4 in the lung. The low
expression of Mrp2 in the small intestine is was unexpected as Mrp2 is highly expressed in the
mouse small intestine (Maher et al, 2005). This was surprising as we had expected either a
compensatory increase resulting from the loss of Mrp1 or no changes in baseline expression.
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2.3.4 Changes in drug disposition and elimination in Mrp1-/- mice
As Mrp1 is expressed in most tissues and there is considerable overlap in transporter expression
and substrate specificity, the loss of Mrp1 appears to have limited effect in terms of
compensation by the remaining transporters at basal levels. After examining the activity or
expression levels of the phase I, phase II and phase III drug metabolizing enzymes, we wanted to
examine the effect the loss of Mrp1 might have on drug disposition. Both wildtype FVB and
FVB Mrp1-/- were challenged with [3H] vincristine, a known high affinity substrate for Mrp1
(Cole et al, 1994). There was an increase in vincristine levels by 3.7, 3.2, and 4.9 fold in the
kidney, small intestine, and epididymis, respectively in the knockout mice as compared to the
wildtype (Table 3). There were no significant changes found in liver, gallbladder, heart, lung,
stomach, spleen, brain, or testes. The lack of compensatory transporter induction appears to
severely alter the elimination profile of vincristine in the Mrp1-/- mice.

2.4 Discussion

This study indicated that loss of Mrp1 leads to alterations extra hepatic phase I, phase II
and phase III metabolizing enzymes and drug disposition. FVB/mrp1-/- mice have increased
cytochrome P450 activity in the kidney, a decreased in sulfotransferase expression in the lung,
and diminished Mrp mRNA levels in both the kidney and lung. Typically, studies involving
compensatory responses after the loss of a transporter focus on examining the liver (Casarett &
Doulls,2008), since this organ is the site of highest detoxification activity and readily eliminates
compounds into the bile. However, the baseline expression of Mrp1 in the liver is exceedingly
low (Roelofsen et al, 1997). Tissues expressing high levels of Mrp1 include the lung, kidney,
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heart, adrenal, and testes (Reviewed in Klaassen and Aleksunes, 2010), while the small intestine
has low levels (Peng et al, 1999, Zimmerman et al. 2005). The lung is the only organ that
singularly functions as an excretory and intake organ, save the skin. Therefore it is exposed to
both environmental and endogenous compounds, both native and biotransformed. The kidney
and small intestine have high metabolic activity, and function in both toxicant uptake and
elimination. Thus, we investigated compensatory changes in Mrp1 knockout mice in these three
tissues.

Mice lacking Mrp1 had increases in 16α-OH, 7α/15β-OH, 16β-OH,testosterone
hydroxylation activationin their kidneys, which correspond to Cyp2c7, 2a1, and 3a4. Cyp 2c7
and Cyp2a1 are female predominate, and Mrp1-/- mice have been shown to have lower levels of
circulating testosterone and higher levels of circulating estradiol (Sivils et al, 2010).
Testosterone has been shown to have an inhibitory effect on Cyp2a1 expression, although the
effect on Cyp2c7 expression is inconclusive (Waxmam et al, 1985, Bandiera et al, 1992, Ortiz de
Montallano, 2005).

Cyp 3a4 activity has also be shown to be modulated by steroids, as

androgens induced triazolam 4-hydroxylation, but reduced TZM 1-hydroxylation by Cyp3a4
(Nakamura et al, 2002, Cheung et al, 2006, Yu et al, 2005, reviewed Walbold et al, 2003). Since
Cyp 1a1, 2c7, and 3a4 all metabolize steroids including estrogens, the increased activity in the
kidney of Mrp1 knockout mice may be due to increased serum estrogen (Sivils et al, 2010) and
an attempt to metabolize and eliminate the estrogen via the kidney.

Phase I enzyme activity was not altered in the livers of Mrp1 knockout mice (Bain and
Feldman, 2003). This is likely due to the constitutively high P450 and low Mrp1 expression in
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the liver (Casarett and Doulls, 2008, Cole et al, 1998)

In contrast, the liver has high Mrp2

expression and several Cyp450s are differentially expressed (Chu et al, 2006). There was a 2.2fold induction of Cyp7a1 and a 2.5-fold reduction in males, and a 10-, and 2.0-fold reduction in
Cyp4a14, Cyp 2b13 in females Cyp2b9 , in the livers of Mrp2 -/- mice.(Chu et al, 20006)which
was hypothesized to be due to downstream changes in phase ll and phase lll metabolism (Chu et
al, 2006). The loss of Mrp2 leads to an increase in serum bilirubin and bile salt levels, and an
elevated rate of excretion of bile salts in the bile; leading to a decreased accumulation bile salt
levels in the liver. ,The decreased bile acid levels up regulate Cyp7a1expression via a negative
feedback mechanism(Hunt et al, 2000, Moffit et al, 2006, Eloranta et al, 2005). Both Cyp2b9 and
2b13 are expressed in the liver, however there substrates, are as of yet undetermined (Hashita et
al, 2008). Interestingly, the one P450 that showed a 2.65-fold reduction in the liver of Mpr1-/mice was the male specific Cyp2c13, although this was not significant due to high variability
(Bain and Feldman, 2003). This enzyme hydroxylates testosterone at the 6β and15α position and
progesterone at the 6β and 16α position (Kitareewan and Walz, 1994), and its reduction in mice
lacking Mrp1 was probably due to the decreased levels of serum testosterone (Sivils et al, 2010)

Phase II compensation due to the loss of an ABCC transporter has been shown to date in
two studies.

Our laboratory has previously shown that there is an increase in hepatic

glucuronosyltransferase activity and decreased sulfotransferase activity in Mrp1 knockout mice
(Bain and Feldman 2003). Additionally, Mrp4 knockout mice have increased hepatic Sult2a
levels (Mahfoud et al, 2004). In the present study Sult1a1 expression was reduced in the lung
which may be related to alterations in serum steroid levels. Sult1a1 is the only Sult with higher
expression in the male compared to female mice, which occurs only in the lung (Alnouti, 2006).
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Thus, the reduction in Sult1a1 expression may be due to the increased serum estrogen levels
(Sivils et al, 2010). There were no changes Sult 1a2 levels were below the detection limit in the
small intestine; however Sult 1a2 is expressed at levels far below Sult 1a1 in all tissues thus far
examined (Dooley et al, 2000, Enokizano et al, 2007).

There are several well characterized examples of compensative induction of one or more
MRPs in the response to the loss of an MRP transporter. Surprisingly, mice lacking Mrp1 have
reductions in the extra hepatic expression of other Mrp transporters, including reduced Mrp4
expression in the lung and reduced Mrp2 expression in the kidneys. This is in contrast to
previously published studies dhowing hepatic induction of Mrp2 and Mrp5 in the livers of Mrp1
knockout mice and induction of Mrp3 and Mrp4 in the livers and kidneys of mice and rats
lacking Mrp2 ( Bain and Feldman, 2003, Cho et al, 2006,Chen et al, 2005). The lack of any
significant compensatory induction of extrahepatic Mrps may indicate that outside of the liver
baseline expression levels of the remaining transporters is significant to handle the increased
export burden.
Dosing both FVB and FVB/Mrp1-/- mice with a well characterized non-endogenous
Mrp1 substrate, which overlaps with as many transporters as possible ,may overload the baseline
transport capacity of the remaining transporters, and lead to a detectable compensatory
transporter induction.

To determine whether the changes in phase I, II, and III enzyme expression inj the Mrp1 /- mice lead to changes in drug disposition, we dosed FVB and Mrp1-/- mice with [3H] labeled
vincristine. Increased accumulation of vincristine occurred in the small intestine, kidney, colon
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and epididymis. Aside from the epididmis, vincristine accumulated in the excretory tissues of
mice lacking Mrp1. Although Mrp2 is expressed in the small intestine, highest expression is in
the duodenum and as you move threw to the ileum expression decreases, and finally, Mrp2 is not
expressed in the colon ( Klaassen and Aleksunes, 2010). The high levels found in the intestine
and colon may be due to re absorption and enterohepatic circulation (Maher et al 2005,
Zimmermann et al, 2005). The vincristine begins to accumulate in cells of the gastrointestinal
(GI) track as it moves through during excretion. As we looked at the small intestine as a single
organ we were only able to determine total vincristine accumulation. The change in vincristine
disposition is most likely due to the loss of Mrp1coupled to decreased Mrp2 expression in the
intestine., which in turn leads to the accumulation in excretory tissues as the FVB/Mrp1-/- mouse
attempts to expel the vincristine in the feces (Loe et al, 1996). Increased accumulation in the
kidney is in all probability an attempt to eliminate the excess vincristine via the urine. As the
vincristine moves through the nephron, it is reabsorbed. Without a functional Mrp1 and with the
decreased expression of Mrp2 our study found in the kidneys, the vincristine cannot be extruded
into the blood via Mrp1 nor can be effectively excreted into the urine by Mrp2 (Ines et al, 1994).

The blood-testes barrier serves to protect developing germ cells for toxic insult by
endogenous and exogenouns compounds (Reviewed in Leslie et al, 2004). Mrp1 expression is
high in the murine testes and is considered to be a critical element of the blood-testes barrier
(Bart et al, 2004). With the loss of Mrp1 in the testes, the blood testes barrier would be
compromised, and the vincristine could no longer be pumped out of the testes into the blood
stream, and would rather accumulate in the epididymis to be ultimately eliminated (Tribull et al,
2003). The increased retention of vincristine in the tissues of Mrp1-/- mice may be promising in
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terms of clinical treatment of MDR tumor cells over expressing Mrp1 and Mrp2. A specific
Mrp1/Mrp2 inhibitor may be able to increase the efficacy of cytotoxic drugs that are substrates
for both Mrp1 and Mrp2, by increasing the intercellular concentration and thereby the
antineoplastic activity.

In conclusion, changes in phase I, phase II and phase III enzymes levels and activity may
very well be due less to compensatory changes; rather it may be a result of alterations in serum
steroid levels. All of the enzymes showed at least some degree of sexually dimorphic expression
levels. Therefore, considering the potential clinical implications determining alterations in drug
metabolism and disposition resulting from the loss of or manipulation of Mrp1 activity deserves
further investigation.
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Table 1: Mouse primers used for PCR and Real Time PCR.

Primer

Forward 5’to 3’

Reverse 5’ to 3’

Tm

18S RNA

CATGACCACAGAGTCCATGC

GTCATACCAGGAAATGAGC

63

MRP2

CTGCCTCTTCAGAATCTTAG

CCATCAGTTTCCTTATGGGTCC

58

MRP3

GCTGGCAAGTCTTCCATGAC

CGTGTGCAGGTGGGACAGC

63

MRP4

CATTGCACACAGATTGAACACC

GTCGAGGGCTGTCCATTGG

63

MRP5

GGAATGTATTGCCCAGCTACC

GCAGCAAACATGGCATAGAATC

63

UGT 1a1

CATACAATCATTCGCACATCC

GTGTTGAGACCTGGAGTGG

64

UGT1a2

CTGCTCTGACCTTCGGCATCAGC

CTGGCAGCTGTGCTTTCTTCG

64

UGT2a5

GAAATGCAGCTCTTGAGAACAGC

CAGCGGGATTGTCTGGGTAGC

64

SULT1a1

GTGCATTGGCCATACTAGTC

GTCAGGAAGAGGCTGATTCTTGG

64

SULT1a2

CACTCGCAGCCATCCCTGG

CTCGACCTTAGGACTTCTGC

63
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Table 2: Cytochrome P450 activity determined by testosterone hydroxylation. The activity of
multiple P450 isoforms and their ability to hydroxylate testosterone on different regions of the molecule
was determined (n=6).
Kidney

Lung

FVB

MRP1-/1

FVB

MRP1-/1

Metabolite A

2.31+ 1.9

4.50+ 0.3*

-

-

15ά-OH

22.46+ 10.9

30.53+ 3.1

0.67+ 0.4

0.25+ 0.3

16ά-OH

7.92+ 3.6

12.14+ 1.3*

1.44+ 0.5

1.19+ 0.4

7ά/15β-OH

1.68+ 0.6

2.50+ 0.5*

0.79+ 0.2

0.74+ 0.4

6ά-OH

2.64+1.1

3.45+ 0.3

-

-

6β-OH

9.14+ 4.6

12.67+ 1.6

4.08+ 1.2

3.49+ 0.8

16β-OH

6.74+ 2.3

7.97+ 1.6*

1.83+ 0.3

1.84+ 0.8

13.61+ 3.0

22.79+ 7.1

24.04+ 12.0

Product

2ά-OH
12.31+ 4.17
Significant p< 0.05 (*).
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Table 3. Organ disposition of [3H] vincristine in FVB wildtype and FVB/mrp1-/mice. FVB and Mrp1-/- were injected with 1mg/kg [3H] vincristine sulfate (5.3Ci/mmol),
euthanized at 12 hours, organs removed and weighed. Portions were homogenized in 2%
BSA/PBS and assayed for radioactivity by scintillation counting. Data is presented as average ng
of vincristine/ g of tissue + S.D. Statistical differences were determined by Student’s t-test (*, p<
0.05)

Tissue
Liver
Gall Bladder
Kidney
Colon
Small Intestine
Epididymis
Heart
Lung
Stomach
Spleen
Testes
Brain
Feces

FVB (ng vinc/g)
2.8 + 1.8
5412.5 + 1134.4
11.3 + 8.0
543.0 + 227.7
127.5 + 52.1
111.2 + 40.9
35.2 + 24.0
38.0 + 21.5
1491.9 + 2431.3
275.6 + 79.9
56.7 + 32.9
1.6 + 0.7
829 + 315.1

Mrp1-/- (ng vinc/g)
2.9 + 2.3
7155.1 + 4754.0
36.3 + 11.0
1302.7 + 269.5
468.3 + 35.2
541.3 + 111.1
43.8 + 14.8
64.5 + 12.2
640.4 + 475.7
251.4 + 65.5
100.8 + 53.7
2.1 + 1.4
470.7 + 324.2
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Fold Change
1.0
1.3
3.2*
2.4*
3.7*
4.9*
1.2
1.7
0.4
0.9
1.8
1.3
0.6

Figure legend:
Figure 1. Levels of mRNA in the kidneys, lung, and small intestine of FVB and FVB/Mrp1/- mice mRNA levels of Ugt1a1 (A), Ugt1a2 (B), and Ugt2B(C) were determined by real-time
PCR using primers specific for each Ugt. Data is the mean of 5-6 animals, each run in triplicate.
Data is expressed as number of molecules of RNA/100 ng cDNA + S.D. and data normalized to
18S. Statistical differences (*) were determined by students t-test (p<0.05). ND=Not detected.

Figure 2. mRNA levels of Sult1a1 (A) and Sult1a2 (B)

in the kidneys, lung, and small

intestine ofFVB and FVB/mrp1-/- mice. RNA levels were determined by real-time PCR
using primers specific for each SULT. Data is the mean of 5-6 animals, each run in triplicate.
Data is expressed as number of molecules of RNA / 100 ng cDNA +/- S.D. and normalized to
18S. Statistical differences (*) were determined by students t-test (p<0.05). ND=Not detected.

Figure 3. MRP mRNA levels in FVB and FVB/mrp1-/- mice, in the kidneys, lung, and small
intestine. RNA levels were determined by real-time PCR using primers specific for each Mrp2
(a), Mrp3 (b), Mrp4 (c), and Mrp5 (d). The only significant changes were decreased expression
of Mrp2 in the kidney. Data is the mean of 5-6 animals, each run in triplicate. Data is expressed
as number of molecules of RNA/100 ng cDNA, +/- S.D. and normalized to 18S. Statistical
differences (*) were determined by students t-test (p<0.05). ND=Not detected.
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Chapter 3: Mice lacking Mrp1 have reduced testicular steroid hormone levels
and alterations in steroid biosynthetic enzymes
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Abstract
The multidrug resistance-associated protein 1 (MRP1/ABCC1) is a member of the ABC active
transporter family that can transport several steroid hormone conjugates, including 17β-estradiol
glucuronide, dehydroepiandrosterone sulfate (DHEAS), and estrone 3-sulfate. The present study
investigated the role that MRP1 plays in maintaining proper hormone levels in the serum and
testes. Serum and testicular steroid hormone levels were examined in both wild-type mice and
Mrp1 null mice. Serum testosterone levels were reduced 5-fold in mice lacking Mrp1, while
testicular androstenedione, testosterone, estradiol, and dehydroepiandrosterone (DHEA) were
significantly reduced by 1.7- to 4.5-fold in Mrp1 knockout mice. Investigating the mechanisms
responsible for the reduction in steroid hormones in Mrp1-/- mice revealed no differences in the
expression or activity of enzymes that inactivate steroids, the sulfotransferases or
glucuronosyltransferases.
altered.

However, steroid biosynthetic enzyme levels in the testes were

Cyp17 protein levels were increased by 1.6-fold, while Cyp17 activity using

progesterone as a substrate was also increased by 1.4-2.0-fold in mice lacking Mrp1.
Additionally, the ratio of 17β-hydroxysteroid dehydrogenase to 3β- hydroxysteroid
dehydrogenase, and steroidogenic factor 1 to 3β-hydroxysteroid dehydrogenase were
significantly increased in the testes of Mrp1-/- mice. These results indicate that Mrp1-/- mice
have lowered steroid hormones levels, and suggests that upregulation of steroid biosynthetic
enzymes may be an attempt to maintain proper steroid hormone homeostasis.

Key Words: Multidrug resistance-associated protein 1, ATP-binding cassette, testosterone,
androstenedione, testes, Cyp17, 17β -hydroxysteroid dehydrogenase
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3.1. Introduction

Members of the multidrug resistance-associated protein (MRP or ABCC) subfamily of
transporters are responsible for the elimination of numerous endogenous ligands, drugs, and
toxicants (Deeley, Westlake et al. 2006; Bakos and Homolya 2007). One member of the family,
the multidrug resistance-associated protein 1 (MRP1 or ABCC1), extrudes phase II metabolites
of steroid hormones such as 17β-estradiol glucuronide, dehydroepiandrosterone sulfate
(DHEAS), and estrone 3-sulfate (Loe, Almquist et al. 1996; Qian, Song et al. 2001; Zelcer, Reid
et al. 2003; Leslie, Deeley et al. 2005), along with other endogenous and exogenous substrates.
MRP1 and other members of the ABCC family help maintain the blood-brain barrier, bloodcerebrospinal fluid barrier, and the blood-testes barrier, by removing xenobiotics and
endogenous compounds from the nervous system or testes and transporting them back into the
bloodstream (Wijnholds, Scheffer et al. 1998; Dallas, Zhu et al. 2003; Nies, Jedlitschky et al.
2004). In human tissues, MRP1 is expressed in the testes, adrenals, prostate, skin, esophagus,
small intestine, large intestine, lung, heart, amnion epithelium, and the pancreas (Flens, Zaman et
al. 1996; Zelcer, Reid et al. 2003; Aye, Paxton et al. 2007). In mice, Mrp1 is expressed in testes
in both Sertoli and Leydig cells, as well as in the colon, heart, small intestine, kidney, and lungs
(Stride, Valdimarsson et al. 1996; Peng, Cluzeaud et al. 1999). Organs that synthesize and
respond to steroid hormones, such as the adrenals, testes and ovaries appear to have the highest
levels of expression (Maher, Slitt et al. 2005).

In addition to cellular and organ localization, evidence from knockout mice also supports
the idea that one function of MRP1 is to protect cells from damage. For example, etoposide
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treatment damages the mucosal layer of the tongue in mice lacking Mrp1 (Wijnholds, Scheffer et
al. 1998), while vincristine treatment of Mrp1 knockout mice results in toxicity to the bone
marrow and reduces survival by 4-fold (Johnson, Finch et al. 2001; van Tellingen, Buckle et al.
2003).

In addition, the presence of Mrp1 reduces tissue accumulation of the antibiotic

grepafloxacin (Sasabe, Kato et al. 2004; Li, Kato et al. 2005). Triple knockout mice that lack
Mdr1a, Mdr1b, and Mrp1, exposed to cigarette smoke for 6 months, had reduced numbers of
inflammatory cells and IL-8 levels in the lungs of mice compared to control mice, which
suggests an impaired inflammatory response (van der Deen, Timens et al. 2007). In the testes,
Mrp1 is thought to play a role in maintaining the blood-testes barrier, preventing accumulation of
toxicants as well as preventing the build-up of estrogen-like compounds (Wijnholds, Scheffer et
al. 1998; Tribull, Bruner et al. 2003).

Although it has long been known that MRP1 can transport a variety of steroid hormones
using in vitro models, its role in modulation of steroid hormone homeostasis in an animal model
has not been previously described. In the testes, hormones are derived from pregnenolone after
conversion through two different potential pathways. Th Δ5 steroidogenic pathway involves the
conversion of pregnenolone to DHEA and androstenediol, prior to the formation of testosterone.
This is the dominant pathway in humans (Fluck, Miller et al. 2003). The Δ4 pathway begins with
the conversion of pregnenolone into progesterone, with androstenedione ultimately being
converted into testosterone. This is the predominant pathway in rodents (Fevold, Lorence et al.
1989; Mathieu, Auchus et al. 2002), although 3β-hydroxysteroid dehydrogenase can convert
hormones from the Δ5 pathway into substrates involved in theΔ4 pathway.
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Testosterone and estradiol are both synthesized in the testes. Although both are
needed for proper testicular functioning and for spermatogenesis, estradiol concentrations must
be maintained at low levels to prevent testicular feminization and protect developing
spermatozoa.

To maintain proper estrogen levels, sulfotransferase 1E1 (sult1e1 or EST)

catalyzes the formation of estrone 3-sulfate, which inactivates the hormone (reviewed in (Strott
1996; Song and Melner 2000). Because the resulting product is hydrophilic, investigators have
hypothesized that estrone 3-sulfate is transported out via Mrp1 (Qian, Song et al. 2001).
Therefore, this study examined the differences in steroid hormones levels and steroid hormone
metabolizing enzymes in Mrp1 knockout mice to determine whether Mrp1 played a role in
regulating circulating and testicular steroid hormone levels.

3.2. Materials and methods
3.2.1 FVB and FVB/mrp1-/- mice
Three sets of male FVB (control or wild-type mice) and Mrp1 knockout mice
(FVB/Mrp1-/-) were obtained from Taconic Farms (Germantown, NY) at 4-5 weeks of age.
They were individually housed until 10 weeks of age at 25+2oC and 50% humidity and fed
TestDiet 5001 rodent chow (Richmond, IN) before euthanization via a CO2 overdose.

All

experiments were approved by the Institutional Animal Care and Use Committee (IACUC) at the
University of Texas at El Paso. In the first set of mice, testes, livers, and blood were removed
from six animals from each strain.

One testis was snap-frozen in liquid nitrogen to prepare

cytosol and microsomes, while the other was placed in Tri-Reagent (Sigma Chemical, St. Louis,
MO) to obtain RNA. All samples were stored at -80oC. Blood was collected, serum prepared by
centrifugation, and stored at –20oC for steroid hormone analyses. In the second and third set of
53

experiments, six additional male FVB and Mrp1-/- mice were obtained, housed, and euthanized
as above. The testes were removed and weighed. Blood was collected, serum prepared by
centrifugation, and stored at –20oC for steroid hormone analyses. One testis was snap-frozen in
liquid nitrogen to prepare cytosol and microsomes. The other testis was homogenized in 0.1M
potassium phosphate buffer, pH 7.4, and testicular steroid hormones were extracted twice by the
addition of 2mL of diethyl ether. The two extracts were combined, evaporated under nitrogen
and resuspended in 1mL phosphate buffer (Jeyaraj, Grossman et al. 2005). The aqueous portions
of the testes extracts were used to examine dehydroepiandrosterone sulfate (DHEAS). Extracts
were stored at –20oC.

3.2.2 Steroid hormone levels in serum and testes

Testosterone, progesterone, estradiol, and DHEAS concentrations were determined by EIA kits
(Calbiotech, Spring Valley, CA for DHEAS; Cayman Chemical, Ann Arbor, MI for testosterone,
progesterone, and estradiol), while androstenedione and DHEA concentrations were determined
by RIA (Diagnostic Systems Laboratories, Webster, TX).

To determine testosterone

concentrations, 10µL of a 1:20 dilution of the testes extracts or 10µL of serum was used. For
progesterone concentrations, 25µL of the testes extract and serum were used. For estradiol
concentrations, 25µL serum and 100µL of the testicular extracts was used. For androstenedione,
5µL of both serum and testes extract were used. For DHEA, 50µL of serum and 100µL of the
testicular extracts were used, while for DHEAS, 1µL of serum or 100µL of the aqueous portion
of the testes sample was used. All samples were run in duplicate or triplicate. Results are
expressed as amount of hormone per mL serum or amount of hormone per gram of tissue.
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3.2.3 Changes in RNA abundance by QPCR

Total RNA from the testes and liver of each mouse was isolated using TRI-Reagent (Sigma, St.
Louis, MO) and then treated with RNase-free DNase. To prepare cDNA, total RNA (2µg) was
incubated with 50ng random hexamers, RNAsin, 10mM dNTP mix, and 200U Moloney murine
leukemia virus (MMLV) reverse transcriptase at 37oC for 1 hour.

Quantitative PCR was

performed in Bio-Rad’s I-Cycler (Hercules, CA) using 0.2mM dNTPs, 0.25X Sybr green, 1U
Taq polymerase (SABiosciences, Frederick, MD), along individual sets of primers for
uridineglucuronosyltransferase 2b (Ugt2b), sulfotransferase 1e1 (Sult1e1), 3β-hydroxysteroid
dehydrogenase 1 (3β-HSD1), 17β-HSD3, androgen receptor (AR), lutenizing hormone receptor
(LHR), Cyp17, Cyp11A, steriodogenic acute regulatory protein (StAR), Cyp19, estrogen
receptor α (Esr1), estrogen receptor β (Esr2), and steroidogenic factor-1 (SF-1) (Table 1). 18S
rRNA was used as the housekeeper for Ugt2b and Sult1e1 to facilitate comparisons between the
liver and testes, while GAPDH were used as housekeeper for all other genes. All PCR products
had a denaturing step of 95°C for 15 seconds, an annealing /extension step at 61oC (51oC for
GAPDH) for 1 minute for a total of 40 cycles. The cycle threshold values obtained from the
real-time PCR were converted into starting number of molecules per 100ng cDNA using known
concentrations of the specific gene product, which was normalized to the housekeeping gene.
The standards were prepared by RT-PCR and sequenced to confirm their identity.

3.2.4 Estrogen sulfotransferase activity
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One testes and a portion of the liver from each mouse was individually homogenized in buffer
(250mM sucrose, 1mM EDTA, 10mM Tris, pH 7.4, containing 2µg/mL each aprotinin,
leupeptin, and pepstatin) with a Dounce homogenizer.

Microsomes were prepared by

centrifuging the homogenate at 10,000xg for 10 minutes. The supernatant was removed and
centrifuged at 100,000xg for 60 minutes. The cytosol was removed and stored at -80oC. The
microsomal pellet was resuspended and recentrifuged.

The final pellet containing the

microsomes was resuspended in homogenization buffer containing 10% glycerol and stored at –
80oC. Protein concentrations were determined according to Bradford (Bradford 1976) using
bovine serum albumin as the standard. Estrogen sulfotransferase (EST) activity was determined
by preincubating 100µg of either liver or testes cytosolic protein in 50 mM Tris-HCl, 7mM
MgCl2 buffer, pH 7.4, containing 100nM [3H] estradiol (100Ci/mmol, American Radiolabeled
Chemicals, St. Louis, MO) at 37oC for 3 minutes. The reactions were started by the addition of
20µM PAPS and incubated for 30 minutes at 37oC. The reactions were terminated by the
addition of 250 mM Tris-HCl (pH 8.7) to alkalinize the solution and chloroform to separate the
estradiol from its sulfated product (Miki, Nakata et al. 2002). EST formation was determined by
removing 100µl of the aqueous phase and counting on a liquid scintillation counter.

3.2.5 Immunoblotting

Testicular microsomal proteins (2-20µg) were separated on a 12% SDS-polyacrylamide gel and
transferred to nitrocellulose (Harlow and Lane 1988). The nitrocellulose membrane was blocked
in 5% nonfat milk and then incubated with the primary antibody in TBST (Ugt2b:1:400 dilution;
Cyp17: 1:200 dilution; both from Santa Cruz Biotechnology, Santa Cruz, CA). After rinsing, the
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blot was incubated with the appropriate secondary antibody (1:200-1:5000 dilution; Santa Cruz)
in TBST. The blot was developed and the intensity of the bands quantified using the ImmunStar
AP kit (BioRad) or the Luminol HRP kit (Santa Cruz) on a ChemiDoc XRS molecular imager
(BioRad). Blots were stripped in 100mM 2-mercaptoethanol, 2% SDS, 62.5mM Tris-HCl, pH
6.7 at 50oC. After rinsing in TBST, blots were reprobed using an actin (1:500 dilution; Sigma)
or GAPDH antibody (1:1000 dilution; Imgenex, San Diego, CA) as a loading control, and were
quantified as above.

3.2.6 Progesterone metabolism by CYP17

CYP17 hydroxylase assays were performed to assess hormone production using
progesterone as a precursor. Testicular microsomal protein (50µg) was preincubated in 100mM
potassium phosphate buffer (pH 7.4) containing 1µM([3H]progesterone (120Ci/mmol, American
Radiolabeled Chemicals) in a shaking water bath at 37oC for 3 minutes. 1mM NADPH was
added to initiate the reactions and the tubes were incubated for 20 minutes. The reaction was
terminated and progesterone metabolites were extracted twice by the addition of 2mL ethyl
acetate. The extracts were evaporated under nitrogen, dissolved in 35µL ethyl acetate, and
spotted onto TLC plates. The TLC plates were resolved using a 3:1 mixture of chloroform and
ethyl acetate. The identities of metabolites were determined by co-migration of authentic
standards (Steraloids, Newport, RI). The TLC plates were exposed to autoradiography film, and
individual metabolites were cut from the plates and quantitated by scintillation counting to
determine the specific activity for each metabolite.
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3.2.7 Statistical Analysis

Samples from each group were averaged and significant differences were determined by
Student’s t-test or Mann-Whitney (p < 0.05) using Graphpad Prism Software (San Diego, CA).
Linear regression analyses were also performed using Graphpad Prism.

3.3 Results

3.3.1 Reductions in steroid hormone concentrations in Mrp1 knockout mice

Because MRP1 is known to transport several steroid hormones in vitro, their
concentrations in the serum of wild-type and Mrp1 knockout mice were examined. Serum
testosterone concentrations were reduced by 5-fold in the FVB/Mrp1-/- mice, although there
were no differences in serum progesterone, androstenedione, DHEA, DHEAS, or estradiol levels
(Figure 1). We hypothesized that since testosterone concentrations were reduced in the serum,
its levels in the testes would be increased.

Surprisingly, testosterone levels were actually

reduced by 2.4-fold in the testes of mice lacking Mrp1, indicating low testosterone production
(Figure 2). Progesterone levels were similar between both strains of mice. However, the other
progesterone metabolites examined, androstenedione and estradiol, were significantly reduced by
4.5-fold and 1.7-fold, respectively, in Mrp1 knockout mice.
concentrations were lowered by 2.1-fold (Figure 2).
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Likewise, testicular DHEA

Next, we determined whether testicular hormone concentrations correlated with one
another using linear regression. Progesterone levels tended not to correlate with the other
hormones, but the levels of DHEA, androstenedione, testosterone, and estradiol did highly
correlate with one another (Table 2). Indeed, when comparing the ratio of two hormones in the
testes of an individual mouse, there is always a higher level of progesterone in the Mrp1
knockout mice versus the control mice, relative to the other downstream hormones, including
androstenedione and testosterone, as well as DHEA (Table 3). In contrast, there is a trend
towards a reduction in testicular androstenedione levels relative to all other downstream
hormones. The changes in steroid hormone concentrations in the Mrp1-/- mice, coupled with a
higher relative ratio of progesterone versus androstenedione suggests that either (1) there is
increased conjugation, inactivation, and/or elimination of androstenedione, testosterone, and
estradiol in mice lacking Mrp1, or (2) an enzyme in the steroid hormone biosynthetic pathway is
altered in mice lacking Mrp1, likely immediately preceding the formation of androstenedione.

3.3.2 Alterations in steroid conjugation

To test these hypotheses, the expression and activity of sulfotransferase 1e1 (SULT1E1)
and uridine diphosphoglucuronoysltransferase 2b (UGT2B) were examined in the testes to
determine whether increased conjugation was responsible for the reductions in testicular steroid
hormone concentrations. There were no differences in SULT1E1 RNA expression or enzyme
activity or in Ugt2b RNA and protein levels in the testes of wild-type and Mrp1-/- mice (Figure
3). There are also no changes in SULT1E1 activity and in UGT2b RNA expression in the liver
of the two strains of mice (data not shown). Thus, an increase in androgen inactivation due to
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increased conjugation does not appear to cause the reductions in testicular androstenedione,
testosterone, or estradiol levels.

3.3.3. Changes in steroid biosynthetic enzymes

To test the second hypothesis, the levels of steroidogenic enzyme mRNA expression in the testes
along with the transcription factor SF-1, as well as the androgen, estrogen, and lutenizing
hormone receptors, were examined by QPCR to determine whether there were differences
between control and Mrp1 knockout mice. There were no changes in the expression of StAR,
Cyp11a, Cyp19, LHR, ERα, or ERβ mRNA levels (data not shown). AR levels were increased in
the mice lacking Mrp1, but this was not quite statistically significant (p=0.06; data not shown).
We also examined changes in other enzymes in the steroid biosynthetic pathway, including 3βHSD1, which catalyzes the conversion of pregnenolone into progesterone, 17β-HSD3, which
converts androstenedione into testosterone, and SF-1, which is a transcription factor involved in
regulation of the enzymes in this pathway. Levels of 3β-HSD1 in the testes were unchanged
between wild-type and Mrp1-/- mice (Table 4). 17β-HSD3 expression appeared to be
upregulated in the mice lacking Mrp1, but this was not quite statistically significant (p=0.068;
Table 4). However, the ratio of 17β-HSD3/3β-HSD1 expression and SF-1/3β-HSD1 in each
individual mouse was significantly increased (Table 4). This indicates that mice lacking Mrp1
have upregulated steroidogenic gene expression to compensate for the lowered production of
hormones.
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4

Ultimately, it is the conversion of progesterone to androstenedione along the

pathway that

appears to be most impacted, because progesterone levels in the testes were similar between
FVB and Mrp1-/- mice while androstenedione levels were reduced in Mrp1-/- mice. Therefore,
we examined Cyp17 protein and activity. Cyp17 catalyzes the formation of 17-OH progesterone
from progesterone, and then the formation of androstenedione from 17-OH progesterone.
Transcript levels of Cyp17 were increased by 1.6-fold but this was not quite statistically different
(data not shown). There was a significant 1.6-fold increase in Cyp17 protein in the testes of
Mrp1 knockout mice (Figure 4A and B). The increase in protein expression was corroborated by
with an increase in Cyp17 activity, with the production of 17-OH progesterone increased by 1.4fold and the production of androstenedione increased by 2- fold (Figure 4C).

Taken together,

these data indicate that mice lacking the Mrp1 transporter have upregulated steroid biosynthetic
enzymes in an attempt to mitigate the reduction in serum and testicular hormones.

3.4. Discussion

Maintaining steroid hormone homeostasis is essential for ensuring sexual differentiation,
development, and reproduction. Estrogens are required for proper development and maintenance
of the male reproductive tract, as well as for male fertility ((Hess 2003; Akingbemi 2005), but
too high of estrogen levels have shown to be detrimental (Akingbemi 2005; Delbès, Levacher et
al. 2006; Toppari 2008). For example, administration of exogenous estradiol to adult male rats
resulted in significant decreases in serum and testicular testosterone levels. Depending on the
estradiol concentration administered, serum testosterone levels were reduced between 4.4- to 18-
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fold while testicular testosterone levels were reduced 7.8- to 11.6-fold (D'Souza, Gill-Sharma et
al. 2005). Although the true endogenous function of MRP1 is not known, it has been
hypothesized that MRP1 acts to maintain steroid hormone homeostasis because it can actively
transport the estrogen metabolites 17β-estradiol glucuronide and estrone 3-sulfate, as well as
DHEAS (Loe, Almquist et al. 1996; Zelcer, Reid et al. 2003; Chen, Guo et al. 2005).

Thus,

because Mrp1 expression is quite high in the testes (Flens, Zaman et al. 1996; Stride,
Valdimarsson et al. 1996; Peng, Cluzeaud et al. 1999; Maher, Slitt et al. 2005), one role that
Mrp1 likely plays is to help protect developing spermatozoa from excessively high steroid
hormone levels.

The present study indicates that mice lacking the Mrp1 transporter have reduced concentrations
of androstenedione, testostereone, estradiol, and DHEA in their testes, which to our knowledge,
is the first time tissue reductions in steroid hormone levels has been shown in mice lacking one
of the MRP family members.

Furthermore, linear regression demonstrated that all of the

testicular hormone concentrations correlated with one another except for progesterone. For
example, mice lacking Mrp1 have 2.8- and 3.3-fold more testicular progesterone than
testosterone and androstenedione, respectively. There is a similar trend with a higher ratio of
progesterone to estradiol in the knockout mice. In contrast, testicular androstenedione levels
were lower relative to all other downstream hormones. Although these were not statistically
significant, the hormone ratios in the Mrp1 knockout mice were consistently half the values of
the control mice (0.46-0.55 fold reduction), with all p-values being 0.075-0.099. These data
suggest that the enzyme that converts progesterone into androstenedione, Cyp17, might be
altered in these mice.
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Indeed, Cyp17 protein levels and activity were significantly increased between 1.4- to 2-fold in
the testes of Mrp1 knockout mice. Transcript levels of Cyp17 were also increased by 1.6-fold
but this was not quite statistically different (data not shown). It appears that Cyp17 is therefore
upregulated in Mrp1-/- mouse testes to compensate for the low levels of androstenedione and
testosterone. Although there are several transcription factors that regulate Cyp17 expression, the
predominant one appears to be SF-1 (Nr5a1) (Mellon, Compagnone et al. 1998; Zhang,
Compagnone et al. 2001; Busygina, Vasiliev et al. 2005; Ozbay, Leon et al. 2006; Patel, Beshay
et al. 2009; Shi, Schonemann et al. 2009). SF-1 mRNA levels were increased by 1.7-fold in the
testes of mice lacking Mrp1, although this was not statistically different. Earlier studies had
demonstrated that Cyp17 is regulated by LH secretion via the cAMP signaling pathway (Anakwe
and Payne 1987; Sewer and Waterman 2002). cAMP can increase Cyp17 mRNA levels, and this
effect can be reversed with testosterone exposure (Payne and Sha 1991). These studies suggest
that reduced testosterone levels would cause an increase in Cyp17 expression, consistent with
our findings.

The compensatory upregulation in Cyp17 is corroborated by a 1-6-fold increase in the transcript
levels of 17β-Hsd3, which is the enzyme that converts androtenedione into testosterone. mRNA
levels of the third enzyme in the pathway, 3β-Hsd1, which converts pregenolone into
progesterone, was not altered between the two strains. However, the ratio of 17β-Hsd3 to
3βHsd1 in the testes was significantly increased in mice lacking Mrp1, again suggesting an
upregulation of steroidgenic enzymes after the formation of progesterone. A recent study
determined that testicular 17β-Hsd activity in mice was 0.0153 µmol NAD/minute/ mg protein
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and 3β-Hsd activity was 0.0246µmol NADH/minute/ mg protein ( Harini et al., 2009).This ratio
of 0.62 in their study is in line with our findings in FVB mice, in which the ratio of 17β-Hsd to
3β-Hsd transcript levels was 0.7. In the Mrp1-/- mice, this ratio is much higher, again indicating
an upregulation of 17β-Hsd3. Like Cyp17, 17β-Hsd3 also requires LH and androgen stimulation
to maintain proper expression (Baker, Sha et al. 1997; Tsai-Morris, Khanum et al. 1999).
However, cAMP stimulation is not needed for the expression of 3β-HSD (reviewed in Payne and
Youngblood, 1995). Indeed, the promoter region of 3β-HSD does not have typical steroid
regulatory elements, and so it is assumed that its regulation is mediated by indirect interactions
with other transcription factors, such as Stat proteins and NF-κB (Reichardt, Kaestner et al.
1998; Simard, Ricketts et al. 2005). Because of the indirect interactions, many investigators
consider 3β-HSD to be constitutively expressed enzyme. This is in agreement with the present
study, in which 3β-HSD1 levels were unchanged between the two strains of mice.

Additional potential mechanisms responsible for the reductions in testicular steroid hormones
might be due to changes in cholesterol uptake. However, we did not see changes in StAR gene
expression or in serum cholesterol levels (data not shown), and other studies have not reported
pathological differences in the testes between untreated wild-type and Mrp1 knockout mice that
would indicate altered cholesterol uptake or storage (Wijnholds, Scheffer et al. 1998; Tribull,
Bruner et al. 2003). Mice lacking estrogen sulfotransferase have increased lipid deposition in
Leydig cells, but the accumulation of cholesterol esters is found only in older animals (>18
months).

Two- to three-month old Sult1e-/- mice did not display this phenotype (Tong,

Christenson et al. 2004). The mice in our study were 10 weeks old, and this may have impeded
our ability to detect additional differences such as lipid deposition between the two strains.
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Another mechanism causing changes in steroid hormones might be due to alterations in LH
levels. Serum LH was assayed, but due to the limited amount of serum, we were never able to
obtain values above the detection limits of the assay. However, LH receptor gene expression
was unchanged between the two strains of mice (data not shown). Additionally, reduced steroid
hormone concentrations do not always translate into increased LH levels.

For example,

administration of exogenous estradiol to adult male rats resulted in significant decreases in serum
and testicular testosterone levels. At the lowest concentration of estradiol, both serum FSH and
LH were reduced, but returned to control levels with higher estradiol concentrations (D'Souza,
Gill-Sharma et al. 2005).

Indeed, constant stimulation of gonadal cells by LH may alter

negative feedback loops either in the HPG axis or short loops within the gonadal tissue itself
(Taniguchi, Couse et al. 2007).

It has been long known that steroid hormone concentrations in the gonads are regulated, in part,
through negative feedback loops. However, after chronic stimulation or exposure to a stressor,
an organism may over- or under-compensate for that given perturbation, which has been part of
the difficulty in modeling dose-responses to stressors in the reproductive system (Andersen,
Thomas et al. 2005). The results of the present study indicate that mice have the ability to
compensate for the loss of Mrp1 in their testes by upregulating Cyp17 and altering the ratio of
17βHsd to 3βHsd. The compensatory responces in the testes sen in our study are corroborated by
recent studies in a model fish species. Fathead minnows were exposed to the Cyp19/aromatase
inhibitor fadrozole, which reduced estradiol levels in the serum and ovaries, but increased
Cyp19, Cyp11a, StAR, and FSH receptor mRNA levels (Villeneuve, Mueller et al. 2009).
Exposure to prochloraz, which inhibits both Cyp19 and Cyp17, along with acting as an androgen
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receptor antagonist, reduced testosterone and estradiol levels in the serum of male fish, but
increased testicular expression of AR, Cyp17, and Cyp11a mRNA (Ankley, Bencic et al. 2009).
In both of these studies, the investigators noticed an overcompensation once the stressor was
removed, indicating that the increase in transcript levels serve to offset the reductions in steroid
hormone levels. This is similar to the findings of the current study, in which androstenedione
and testosterone concentrations were low, yet transcript, protein, and activity of Cyp17 were
increased.

In conclusion, mice lacking Mrp1 have reduced concentrations of testicular steroids, including
androstenedione, testostereone, estradiol, and DHEA, but have increased steroid biosynthetic
enzymes. These results suggest that upregulation of steroid biosynthetic enzymes may be an
attempt to maintain proper steroid hormone homeostasis due to the loss of the Mrp1 transporter.
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Figure legend:
Figure 1. Alterations in steroid hormone levels in the serum. All serum samples were run in
duplicate or triplicate. Values are the average + standard deviation of 4-6 mice per group.
Statistical differences (*) were determined using Student’s t-test (p<0.05).

Figure 2. Alterations in steroid hormone concentrations in the testes. All samples testicular
samples were run in duplicate or triplicate. Values are the average + standard deviation for 5-6
mice per group. Statistical differences (*) were determined using Student’s t-test (p<0.05).

Figure 3. Sulfotransferase and glucuronosyltransferase expression and activity do not
differ in the testes of FVB and FVB/Mrp1-/- mice. Sult1e1 and Ugt2b RNA expression was
determined by QPCR (A). The data is expressed in number of molecules/100ng cDNA +
standard deviation.

All samples were normalized to 18S rRNA, with each sample run in

triplicate (n=5=6).

SULT1E1 activity was measured by EST metabolite formation and is
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expressed as pmol/mg protein (B). All samples were run in triplicate (n=6) and the data is
expressed as the average of two separate assays. UGT2B protein levels were determined by
immunoblotting (C) and quantified by densitometry, using GAPDH as a loading control. Data is
expressed as GAPDH-corrected raw intensity values (n=4) and are the average of two separate
blots (D).

Figure 4. The ratio of 17samples were normalized to 18S rRNA, with eaMrp1-/- mice. The
ratio of 17β-HSD3 to 3β-HSD1 mRNA expression (A) and SF-1 to 3βHSD1 (B) for each
individual mouse was calculated. Statistical differences (*) were determined using Student’s ttest. (p<0.05).

Figure 5. Increased testicular Cyp17 protein expression and activity in Mrp1-/- mice.
Protein levels of Cyp17 were determined by immunoblotting (A) and quantified by densitometry
(B), using actin as a loading control. Data is expressed as actin-corrected raw density values
(n=4) and are representative of three separate blots.

Cyp17 activity was determined by

scintillation counting (C), and the data is presented as the average + standard deviation (n=6) of
2 different assays. Statistical differences (*) were determined using Student’s t-test (p<0.05).
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Table 1. Primer sets for QPCR
Name

Accession #

Forward

Reverse

Ugt2b

NP_690024

5’-agttgagacaatgggccaag-3’

5’- gttgggtgaggaaactccaa-3’

Sult1e1

BC034891

5’- tgatgccagaggaaatgatg-3’

5’-tgggaagtggttcttccagt-3’

3βHSD1

BC052659

5’- tagcaagtacagaggcacaagcca-3’

5’- tgtgagtgggttagtgactggcaa-3’

17βHSD3

U66827

5’- taacaagatgaccaagaccgccga-3’

5’- gatttcatgagcaaggcagccaca-3’

AR

X53779

5’-tcaagggaggttacgccaaaggat-3’

5’-acagagccagcggaaagttgtagt-3’

LHR

M81310

5’- cgcagtgttcacgaaggcatttca-3’

5’- tccttctgtaaagttcagcccggt-3’

Esr1

NM_007956

5’- gaaggccgaaatgaaatgggtgct-3’

5’- tcaaggacaaggcagggctattct-3’

Esr2

U81451

5’- agctggctgggctggtatttatct-3’

5’- tgcccacttctctctcacacactt-3’

SF-1

NM_139051

5’- agtctgacttggaaggattggcct-3’

5’- aggtcgatttgatgaccacaccgt-3’

Cyp17

NM_007809

5’- accgtctttcaatgaccggactca-3’

5’- ttatcgtgatgcagtgcccagaga-3’

Cyp11a

NM_019779

5’- caggccaacattaccgagat-3’

5’- cgcagcatctcctgtacctt-3’

StAR

NM_011485

5’- gatgtgggcaaggtgtttc-3’

5’- gcggtccacaagttcttcat-3’

Cyp19

NM_007810

5’- ccaggtgaagacactgcaaa-3’

5’- atttccacaaggtgcctgtc-3’

18S rRNA

NR_003278

5’-ttgacggaagggcaccaccag-3’

5’-cgattccgtgggtggtggtgc-3’

GAPDH

BC096042

5’- gccttccgtgttcctacc-3’

5’- gcctgcttcaccaccttc-3’
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Table 2. Correlations between testicular concentrations of steroid hormones. Hormone
concentrations were determined by EIA or RIA in the testes of FVB and Mrp1-/- mice. Correlations were
determined by linear regression.

Progesterone

Progesterone
------

Androstenedione

Androstenedione
N.S.

DHEA
N.S.

-----

r=0.87
p=0.001

DHEA

-----

Testosterone
Estradiol
N.S. is not significant

Testosterone
r=0.66
p=0.027
r=0.83
p=0.030

Estradiol
N.S.

r=0.71
p=0.021

r=0.87
p=0.001

r=0.83
p=0.003

-----

r=0.79
p=0.004
-----
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Table 3. Ratios of testicular hormones. The ratios of testicular hormones in each individual mouse was
averaged and compared between FVB and Mrp1-/- mice. Statistical differences were determined by
Student’s t-test (p<0.05).

FVB ratio

Mrp1-/- ratio

Progesterone/androstenedione

0.03+0.03

0.10+0.05

3.3*

Progesterone /testosterone

1.5+0.5

4.2+2.0

2.8*

Progesterone /estradiol

10.0+2.2

24.4+16.4

2.4

Progesterone /DHEA

0.8+0.3

1.7+0.8

2.3*

Androstenedione/testosterone

79.3+35.1

44.2+15.7

0.6

Androstenedione/estradiol

591.5+356.9

282.3+97.8

0.5

Androstenedione/DHEA

39.1+23.1

18.0+5.8

0.5

Testosterone/estradiol

7.2+2.3

5.9+3.7

0.8

Testosterone/DHEA

0.5+0.2

0.4+0.2

0.8

0.07+0.03

0.9

Estradiol/DHEA
0.07+0.02
*statistically significant using Student’s t-test (p<0.05)
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Fold difference

Table 4. mRNA concentrations of steroidogenic enzymes. The number of mRNA molecules for
each enzyme was determined by QPCR and normalized to GAPDH expression. Fold difference was
determined by divide the transcript levels in the Mrp1-/- mice by the transcript levels in the FVB mice.
FVB mRNA

Mrp1-/- mRNA

3β-hydroxysteroid dehydrogenase 1

121.8+50.4

122.0+47.8

Fold
difference
1.0

17β-hydroxysteroid dehydrogenase 3

80.0+23.6

130.8+56.2

1.6

83.2+44.3

1.7

SF-1
48.4+21.0
*statistically significant using Student’s t-test (p<0.05)
N=6-7 mice; values are the average of two experiments
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Chapter 4: Both Mrp1 and Mrp4 are Required for Efficient Denritic Cell
Maturation and Activation
Jeffrey Sivils and Kristine Garza

Abstract:
The ATP-binding cassette (ABC) superfamily of membrane transporters uses energy derived from ATP to
eliminate a variety of exogenous and endogenous compounds from cells including steroids, bilirubin,
cAMP, cGMP, leukotriene C4, D4 and E4, prostaglandin E1, E2, Faα. It has been established that Mrp1 and
Mrp4 are required for proper dendritic cell (DC) trafficking from peripheral tissues to lymph nodes and
that Mrp1 may play a role in DC maturation. However, the inhibitor used to determine Mrp1 function in
DC maturation was not specific to Mrp1 and can inhibit most of the Mrp transporters to some degree. As
such, we have verified that murine DC express Mrp 1 - 5 and evaluated the role of Mrp1 and Mrp4 in DC
migration; specifically, we

assessed the function of these two transporters in DC maturation and

activation. Bone marrow-derived DC (BM-DC) from Mrp1 knockout mice were treated with a specific
Mrp4 inhibitor, Sildenafil, to distinguish the possible role of Mrp1 and 4 on DC maturation and
activation. DC maturation was assessed following an 8 day bone marrow culture induced to become DC
and DC activation was induced with lipopolysaccharide (LPS). Maturation and activation wasmeasured
as a function of cell surface marker expression, interleukin (IL)-12 production, and ability to activate T
cells. Sildenafil-treated wild-type (WT) and Mrp1- knock-out (KO) DC showed decreased up-regulation
of activation markers, IL-12 production and ability to activate T cells upon treatment with LPS. Inhibition
of BM-DC activation was more pronounced with the combined loss of Mrp1 and 4. Our data
demonstrates that the absence of Mrp4, and/or Mrp1, reduces LPS-induced BM-DC maturation
suggesting that multiple Mrp’s may participate in DC maturation
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4.1 Introduction.
The multidrug-resistance associated proteins (MRP) initially were thought to be
exclusively involved in the removal of exogenous and endogenous substrates, including
chemotherapy drugs, from cells. The ability of MRPs to pump out a large array of structurally
and functionally dissimilar compounds leads to a multidrug resistance (MDR) phenotype in
which tumor cells fail to respond to a prescribed chemotherapy régime. The last 13 years has
revealed numerous additional endogenous substrates and functions performed by various MRPs.
One particular MRP1 high affinity substrate, leutriene C4 (LTC4), is essential in generating an
effective immune response (Jedlitscky et al, 1994).

Additionally LTB4, LTD4, LTE4 ,

prostaglandin A2 are Mrp1 substrates and LTC4 , LTB4, prostaglandins E1, E2, F2α , cAMP,
cGMP are substrates MRP4 (Leier et al, 1994; Van Aubel et al, 2002;Reid et al, 200), all of
which have been shown to play a role in effective immunity.
Dendritic cells (DC) are the bridge between the innate and adaptive immune systems, and are the
only antigen presenting cells (APC) able to stimulate naïve T cells. DC reside in the periphery to
surveil the interphase between the inside of the body and the environment. DC are continuously
trafficking through peripheral tissue and migrating to draining lymph nodes, carrying and
presenting material collected along the way. Howeer, the increased numbers of DC reach the
lymph nodes upon inflammatory stimuli. Once DC have encountered and processed foreign
antigen within an inflammatory enviroment, they migrate to draining lymph nodes where they
present peptide to and activate naïve Tcells for the induction of an exquisitely specific immune
response. Mrp1 has been shown to berequired for murine DC to efficiently migrate to draining
lymph nodes (Robbiani et al, 2000). Upon extrusion from cells via Mrp1, LTC4 is rapidly
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converted to LTD4 and further to LTE4. Leutrienes then aid in chemotaxis, as DC home in on the
chemokine C-C motif ligand (CCL19) for migration to draining lymph nodes (Robbiani et al,
2000). Blocking LTC4 extrusion from DC significantly inhibits their trafficking to lymph nodes
(Robbiani et al, 2000). Mrp1 appears to be required for the mobilization of tissue DC to draining
lymph nodes.

Taking into consideration the number of high affinity immune modulating

substrates of Mrp1 and the role Mrp1 plays in DC chemotaxis, van de Ven and colleagues
examined the potential role of MRP1 in the maturation of human monocyte-derived DC and the
human acute myloid leukemia cell line MUT-3. The MRP inhibitor, MK571, was added to
maturing interstitial DC on days 0, 3, and 6 (Van de Ven et al, 2006). They saw marked
phenotypic changes relative to control DC, including lower expression of cluster of
differentiation 40 (CD40), cluster of differentiation 86 (CD86), and major histocaptability
complex (MHC), as well as a decreased ability to stimulate T cells (Van de Ven et al, 2006). It
appeared that MRP1 was required for optimal DC maturation; however, MK571 is a global MRP
inhibitor. Thus, the changes seen in DC maturation cannot be solely attributed to alterations in
MRP1 function.
Recently, MRP4 has been show to transport LTB4 and LTC4; Van de Ven and colleagues
therefore examined the role of MRP4 in human DC migration (Van de Ven et al, 2008). Using
Sildenafil (20 and 60 µM), a specific MRP4 inhibitor, and MRP4 short hairpin RNA (shRNA),
they determined that MRP4 is also involved in DC migration (Van de Ven et al, 2008). The
chemical inhibition of MRP4 significantly decreased the percentage of cells that migrated toward
the chemokine C-C motif ligands CCL19 and CCL2 by ~ 80% and ~ 60%, respectively (Van de
Vel et al, 2008). The shMRP4 knock down also decreased DC migration to CCL19 by ~80%
even in the presence of the MRP4 substrates PGE2, LTB4, LTD4 and 8Br-cGMP (Van de Ven et
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al, 2008). In addition to migration studies, Van de Ven and colleges assessed immune function in
Mrp4 and Mrp4/5 knock-out mice. They evaluated bone-marrow (BM) derivedDC (BM-DC)
phenotype between wild type, Mrp4-/- and Mrp4/5-/- mice by flow cytometry. They also
examined what impact the loss of either Mrp4 or Mrp4/5 had on DC ability to stimulate
polyclonal splenocyte cell proliferation and antibody isotype production (Van de Ven et al,
2008). There were no significant alterations in DC migration, phenotype, proliferation, or
antibody isotype production in the absence of MRP4 (Van de Ven et al, 2008). This suggested
that either MRP4 is not required for DC function or that other MRP’s are compensating for the
loss of MRP4.
As Van de Ven and colleagues looked at the involvement of either Mrp1 or Mrp4 and
considering the substrate overlap between the two transporters, we decided to establish whether
Mrp1 and Mrp4 might work in concert to insure effective DC maturation and activation. Our
data suggest that both Mrp1 and Mrp4 are required for efficient DC maturation and activation,
and that with the loss of one, the other may act in a compensatory manner to at least allow partial
DC function.

4.2 Material and Methods:

4.2.1 Animals.
FVB and FVBMRrp -/- mice were purchased from Taconic Farms (Germantown, NY) and
C57BL/6 mice were bred in house. The animals were housed at 25o C and 50% humidity, with a
12-12 day-night cycle, and were provided water and standard pellet chow ad libitum.

At ten

weeks of age, the mice were euthanized with isoflurane and cervical dislocation at which time
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bone marrow was isolated for generation of dendritic cells. All experiments were conducted in
accordance with Institutional Animal Care and Use Committee (IACUC) and the University of
Texas at El Paso guidelines.

4.2.2 Chemicals and Cytokines.
Sildenafil was obtained threw commercial sources and MK571 was purchased from Calbiochem (La Jolla,
CA). Interluekin-4 and granulocye colony stimulating facter (GMC-FS) were purchased from
Paprotech Inc., Rocky Hill, NJ. Lipoploysacharide , Concanavalin A, and paraformaldehyde
were purchased from Sigma Aldrich (St. Louis, MO).

4.2.3 Bone marrow-derived immature dendritic cells (BM-DC). Bone marrow was flushed
from long bones of the indicated mice and red blood cells were lysed using an ammonium
chloride buffer (0.15M NH4Cl and 0.17 M Tris Base) (Sigma). Collected cells were induced to
differentiate into DCs by culturing in RPMI (Invitrogen) media containing 10% Fetal Bovine
Serum (Invitrogen), 1% Penicillin/Streptomycin (Invitrogen), 10 ng/ml GranulocyteMacrophage-ColonyStimulatingFactor(Peprotech), and10 ng/ml Interleukin-4 (Peprotech). Cells
were incubated for eight days @ 37oC, 5% CO2, refreshing the media every other day. BM-DCs
were matured and used either as a single population or were enriched by magnetic activated cell
sorting.

4.2.4 Magnetic Activated Cell Sorting (MACS). MACS was used to enrich bone marrowderived DCs . Briefly, single cell suspensions of BM cultures were incubated in 50% mouse
serum (Rockland) in IMAG buffer (2% FBS in 1X phosphate buffered saline) (Hyclone).
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Antibody-conjugated magnetic beads (Miltenyi) against the dendritic cell marker CD11c, were
added at a ratio of 90 µL for every 106 cells as determined by trypan blue exclusion. Following
incubation on ice, the cells were placed onto a positive selection magnetic column (Miltenyi) and
washed 3 times with IMAG buffer. Upon removal from the magnet, the enriched cell suspension
was released from the column using pressure. Cell purity, as determined by flow cytometry, was
consistently >95%.

4.2.5 Polymerase chain reaction (PCR) –
PCR was performed on and transporter expression determined by extracting total RNA
from BM-DC collected from FVB and FVB/ MRP1-/- mice and prepairing cDNA. Primers were
designed for Mrp 1-5, and PCR reactions were performed at the appropriate annealing
temperature for 40 cycles. PCR products were resolved on a 2% agarose gel and visualized on a
transilluminator.

4.2.6 Enzyme-linked immunosorbant assay (ELISA).
Cellular production of IL-12 was measured by ELISA. Microtiter ELISA plates were
coated with anti-IL-12 capture antibody (100µl/well) over night at 4oC. Plates were blocked at
room temperature with 3% bovine serum albumin in PBS. Cell culture supernatants were added
to the plates (100µl/well) together with detection antibody (0.01µg/ml) for 2 hours. Plates were
washed and strepavidin-HRP was added (0.05µg/ml) for an incubation period of 30 min. Plates
were developed with 3, 3’5, 5’-tetramethylbenzidine (TMB Genscript) and read at 450nm of
spectrometer. Concentrations were calculated against murine recombinant cytokines (BD
Pharmingen).
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4.2.7 Flow Cytometry.
To assess the number of cells expressing and/or the intensity of activation markers,
single cell suspensions were blocked with 50% normal mouse serum (NMS) in FACS buffer (1X
PBS, 10% FBS, and 0.5mM EDTA) for 15 minutes on ice. The cells were then stained with
antibodies for CD11c, MHC II, CD54, CD80 ,and CD86 conjugated to either fluorescein
isothiocyanate (FITC), phycoerytherin (PE), and/or Biotin-streptavidin PECy5 (Pharmingen).
Cells were then fixed in 1% paraformaldehyde. Flow cytometery was performed on a Beckman
Coulter FC500 instrument. Samples were gated for live cells based on forward and side scatter
parameters and 10,000 events per sample were collected and analyzed using CXP software
(Beckman Coulter).

4.2.8 Mixed Lymphocyte Reactions.
BM-DCs from FVB and FVB/Mrp-/- mice were used as stimulators of T cells enriched
from lymph nodes of C57/B mice. BMD-DCs were isolated as described above and matured
either in media alone, with MK571 (25µM), or Sildenafil (20µM), irradiated in an XRad160
gamma-irradiator (Precision Instruments; 1200 rads), then co-cultured with responder T cells at
1:4 and 1:8 ratio. T cell activation was measured 96 hours later as a function of proliferation. To
assess proliferation, cells were pulsed with [3H]-thymidine (PerkinElmer, 0.5 µCi) during the
final 18 hrs of culture (overnight pulse). Cells were harvested and proliferation was determined
by scintillation counting. Unenriched lymph node cells stimulated with Concanavalin A (Con A)
were used as a positive control and T cells in culture medium alone were used as a negative
control.
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4.2.9 T cell isolation and purification
Lymph nodes from C57B1/6 mice were collected, and homogenized to a single cell
suspension. T cells were enriched by MACS, using anti-CD4 for positive selection. Cell
concentration was determined trypan exclusion and counting on a hemocytometer
4.2.10 DC rescue assayTo determine the maturation and activation of DCs grown in the presence of MRP
inhibitor (MK571, 25 µM), two sets of control cells and two sets of cells with the inhibitor were
grown as above. Every two days one set of control cells and one set of treated cells were
collected, centrifuged, and the media was removed. Control cell media was replaced (Figure 1.).
The media for the treatment cells was replaced with the control media, cytokines refreshed and
inhibitor added to 25 µM. On day 6 cells were treated with 10 µM LPS for 24 hr and flow
cytometry was preformed as described above.

Figure 4.1 Assay set up to determine the ability of control cell supernatants to rescue DC
marturation. Lane 1 is the control lane, lane 2 is the control lane used for rescue media added to the
media with MK571, lane 3. Lane 3 is the MK571 rescue lane. Lane 4 is the MK571 inhibited lane.
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4.3 Results
4.3.1 Mrp expression in murine dendritic cells.
Both Mrp1 and Mrp4 expression has been previously described. To test our hypothesis
that Mrp’s are required for DC maturation and activation, we first verified transporter expression
on activated BM-DC. Total messenger RNA (mRNA) was isolated from BM-DCs generated
from FVB and FVB/Mrp1-/- mice .l The BM-DC were harvested after maturation (at the end of
the 8 day BM culture) and following activation with the bacterial endotoxin, LPS. PCR was
performed to determine expression of Mrp1, Mrp2, Mrp3, Mrp4, and Mrp5. As shown in Figure
2, expression was detected for all of the Mrps, with the exception of Mrp2..

4.3.2 Inhibition of Mrp1 and Mrp4 reduces IL-12 production upon BM-DC activation with
LPS but does not alter activation marker expression levels.
Both Mrp1 and Mrp4 have been implicated in DC activation, however the data is still
inconclusive. To establish whether Mrp1 and/or Mrp4 are required for DC activation (response
to microbial stimuli), BM-DC were assessed for IL-12 production and up-regulation of activation
markers upon treatment with LPS. BM-DC, generated from FVB and FVB/Mrp1-/- mice, were
activated with LPS (10 µg/mL) and incubated overnight. Cells were incubated in media alone
(negative control), in in the presence of Mrp general inhibitor, MK571 (25µM), or in the
presence of the Mrp4-specific inhibitor, Sildenafil (20 µM). The general inhibitor (MK571)
prevented the induction of IL-12 production by BM-DC and the inhibition was not enhanced
upon further loss of Mrp1 (Figure 3A). The lack of either Mrp1 or Mrp4 resulted in a significant
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reduction in the production of IL-12 by BM-DC (Figure 3A). The combined loss of Mrp1 and
Mrp4 (FVB/Mrp1-/- + Sildenafil) however, did not act cooperatively to inhibit the ability of BMDC to produce IL-12 in response to LPS.
For DC to effectively interact with T cells and promote an effective immune response, several
activation markers must be up-regulated on the DC surface including the adhesion molecule
CD54 and the co-stimulatory molecule CD86. BM-DC from both FVB and FVB/Mrp1-/- were
treated with MK571 or Sildenafil, and activated with LPS. The cells were stained for the
activation markers CD54 and CD 86, and examined by flow cytometery.

There were no

significant alterations in marker expression between the treated and the untreated control DC, in
either the wildtype or the Mrp1 knock-out BM-DC (Figure 3B).

4.3.3 Inhibition of Mrps during maturation impedes IL-12 production and up-regulation of
markers upon activation with LPS.
To test the second part of our hypothesis, that Mrp1 and/or Mrp4 are needed during
maturation, and that the loss of Mrp1, Mrp4 or both during maturation will alter DC function,
transporter function was inhibited during maturation of BM-DC from both FVB and FVB/Mrp1/-

cells. The inhibitors were added on day 0 and refreshed every 2 days along with the

maturation-inducing cytokines; on day 8, the BM-DC cultures were administered 10 ng/ml of
LPS and assessed for IL-12 production and activation marker expression 24 hrs later. There was
a 5.4 fold decrease in the production of IL-12 in the FVB/Mrp1-/- mice as compared to wildtype
in response to LPS (Figure 4A). Incubation with MK571 led to a significant 5.4 fold decrease in
the wildtype compared to LPS wildtype control and 1.9 fold decrease in knock-out as compared
to the FVB/Mrp1-/- control (Figure 4A). Sildenafil caused a significant 3.3 fold reduction in
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wildtype compared to LPS wildtype control, and a 2.0 fold reduction in the FVB/Mrp1-/- as
compared to FVB/Mrp1-/- LPS control (Figure 4A). Additionally in comparing the treated
FVB/Mrp1-/- against the wildtype LPS control there was a 10.0 and 10.8 fold decrease in IL-12
production by MK571 and Sildenafil, respectively (Figure 4A). Considering the high variability
in IL-12 production between wild type and FVB/Mrp1-/- mice, IL-12 levels were expressed as a
percent the perspective LPS controls. The FVB/Mrp1-/- BM-DC treated with MK571 produce
46.19% less IL-12, and BM-DC treated with Sildenafil produced 39.93% less IL-12 compared
to the LPS control cells. Wildtype BM-DC treated with MK571 produced 81.62% less IL-12 and
Sildenafil-treated cells produced 69.11% less IL-12 than control cells (Figure 4B). It would
appear that losing both Mrp1 and Mrp4 has a greater effect on maturation as measured by IL-12
production than just the loss of Mrp1 or Mrp4 alone.
To further assess the potential role of Mrp1 and/or Mrp4 on DC maturation, the
expression levels of cell surface DC activation markers were assessed. BM-cells from both FVB
and FV/Mrp1-/- were collected and plated as described, except this time only one inhibitor was
used (Sildenafil 20µM) and was again added throughout the maturation period. As before,
following a 24 hr stimulation with LPS on day 8, the BM-DC were stained for CD11c (DCspecific marker), MHC class II, CD54, CD80 and CD86. The flow was gated specifically for DC
using CD11c, and the percentage of cells expressing each marker was ascertained. Foreach
population, 80% of the cells were expressing CD11c (Figure 5); however, the percentage of FVB
and FVB/Mrp1-/- CD11c+ cells expressing the activation markers was significantly altered
(summarized in Table1). In adition, the FVB-derived DC treated with the inhibitor also had a
significantly lower percentage of cells expressing MHC class II, CD54, CD80 and CD86 (Table
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1). A change in the percentage of Mrp-4 inhibitor-treated FVB/Mrp1-/- cells expressing DC
activation markers was only decreased with respect to CD54 expression (Figure 5).
Also evaluated was mean intensity or relative number of individual cell surface markers
on the cell. The only significant difference between wildtype DC and knock-out DC was in the
Sildenafil-treated knockout BM-DC. CD54 on the knockout DC was expressed 5.48 fold lower
than on the wildtype cells when Mrp4 was also blocked (Figure 6). Together, the IL-12 data and
the activation marker data suggest that both Mrp1 and Mrp4 are critical for DC maturation. The
lack of either transporter significantly inhibits IL-12 production and significantly alters the
percentage of DC that upregulate activation markers suggesting that both transporters and
necessary to generate DC that can properly respond to microbial stimulation.

4.3.4 Optimal T cell activation appears to require both Mrp1 and Mrp4 as determined by
MLR
In order to bridge the innate branch of the immune system to the acquired, DC need to present
antigen to T cells, this in turn triggers the adaptive response. To determine the role of Mrp1
and/or Mrp4 play in the ability of DC to activate naïve T cells a Mixed Lymphocyte Reaction
(MLR) was performed with BM-DC acquired from both FVB and FVB/Mrp1-/- mice. The DC
were matured either in the presence of MK571 (25µM), Sildenafil (20µM), or media alone; on
day eight, the cells were irradiated and co-incubated with T cells isolated from C57Bl/6 mice.
Seventy two hours later, the co-cultures were pulsed for 24 hours with [3H]-thymidine.
As shown in Figure 7, DC harvested from FVB/Mrp1-/- mice were not as proficient at activating
allogeneic T cells as those from wild type FVB mice (Figure 7A). The addition of MK571
reduced the ability of wild type and FVB/Mrp1-/- BM-DC to activate T cells 2.0 and 1.4 fold,
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respectively. The FVB/Mrp1-/- mice, both untreated and treated with MK571, showed a similar
ability to stimulate T cells as the wildtype treated with MK571 (Figure 7A). Both wild type and
knock-out DC treated with Sildenafil were 2.9 and 3.5 fold less efficient in stimulating
allogeneic T cells, respectively, and less efficient than the cells treated with MK571 (Figure 7A).
Curiously, even when cells were treated with the T cell mitogen ConA as a positive control,
Sildenafil inhibited BM-DC effectiveness of activating allogeneic T cells.

The significant

differences in the ability of BM-DC to activate allogenic T cells in more readily seen when
comparing proliferative responses of T cells (at a DC to T cell ratio of 1:4) relative to the
positive control of Con A or wild type (Figure 7B).

4.3.5 Rescue of DC maturation in chemically inhibited BM-DC.
As there are several immune modulating substrates for both Mrp1 and Mrp4 we have
hypothesized that DC expel an autocrine factor via the Mrps while undergoing maturation, which
is required to complete maturation. To determine if Mr1 and/or Mrp4 is pumping out a molecule
or molecules having autocine action on the DC, required for maturation and/or activation, a
rescue experiment was performed. It was hypothesized the unknown factors released into the
media through the transporters by control DC during maturation could be harvested and used to
rescue maturation of BM-DC maturing in the presence of the inhibitor. Two sets of BM-DC were
matured in media alone and two sets in the presence of MK571 (25 µM). One media and one
inhibited set BM-DC were allowed to mature as previously described. For the remaining set of
inhibitor-treated BM-DC, the media was removed every two days and was replaced with the
media from the remaining control BM-DC plus with fresh media and inhibitor (to maintain
chemical inhibition of the Mrps). After 6 days of maturation and an additional 24 hours of
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activation with LPS, BM-DC were examined for activation markers expressed by flow
cytometry. As shown in Figure 8, the mean intensity of DC cell surface activation markers,
CD54, CD80, and CD86, on the cells expressing CD11c statistically increased on the rescued
cells. This preliminary data suggests that the supernatants from normal maturing BM-DC can
recover DC maturation when Mrps are inhibited.

4.4 Discussion
Several groups have looked at the potential roles of MRP1 or MRP4 play in DC function.
Inhibition of MRP1or MRP4 function blocked DC migration to lymph nodes, (Robbiani, Finch
et al. 2000; Honig, Fu et al. 2003; van de Ven, Scheffer et al. 2008). Initially the loss of MRP1
was thought to obstruct DC differentiation however this was determined with using MK571 to
block MRP1, which has since been determined to inhibit most of the MRPs to some extent (van
de Ven, de Jong et al. 2006). Later, the same group looked specifically at Mrp4 in mice; it was
determined that murine Mrp4 was not required for DC migration or for mounting an immune
response; this did not exclude Mrp1 from the previous study (van de Ven, de Jong et al. 2006;
van de Ven, de Groot et al. 2009). Considering the functional and substrate overlap seen in the
more traditional roles played by the MRPs in the elimination of endogenous and exogenous
compounds, and that neither Mrp1 nor Mrp4 knock-out mice are severely immune-compromised,
we decided to look at the potential role of both Mrp1 and Mrp4 in DC function (Wijnholds et al,
1997, van de Ven et al, 2009). Using an Mrp1 knock-out mouse, the global Mrp inhibitor
MK571 and the Mrp4-specific inhibitor, Sildenafil, we concluded that both Mrp1 and Mrp4 are
required for DC maturation and ultimately effective DC induction of adaptive immunity.
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To confirm the expression of Mrp1 and Mrp4, mRNA was extracted from activated FVB
mouse BM-DC, reversed transcribed and PCR was performed. All but Mrp2 was present; this
concurs with determined human DC MRP expression (Skazik, Heise et al. 2008)(Fig. 1).
To look at the possible role of Mrp1 and Mrp4 on DC activation, DC were cultured as
described in Materials and Methods. On day 8, DC were stimulated with LPS. BM-DC activation
was measured as a function of IL-12 production and expression of cell surface activations
markers. We next wanted to determine if inhibiting the transporters either together or one at a
time would impair DC ability to initiate an immune response. The global MRP inhibitor, MK571
has been shown to effectively block Mrp1 mediated efflux of known Mrp1 substrates (van de
Ven et al, 2006). Sildenafil has also been shown to effectively inhibit Mrp4 mediated efflux of
Mrp4 substrates (van de Ven et al, 2008). The production of IL-12 in the wild type and the Mrp1
-/- cells was significantly lowered by the loss of either Mrp1 and/or Mrp4. However blocking
either Mrp1 or Mrp4 with the Mrp inhibitors at the time of activation did not affect DC ability to
up-regulate the activation markers CD54 or CD86 when exposed to LPS. Conversely, the
decrease in IL-12 production may hamper the responding T cells and attenuate the immune
response. Even considering BM-DC IL12 production was decreased by inhibiting Mrp function
during activation, we concluded that any significant effect on DC function occur prior to their
activation, hence we looked at DC maturation.
BM-DC were cultured as above, except the inhibitors were added on day zero and
refreshed every two days. Previously inhibition by MK571 had been shown to reduce the
production of IL12 in activated DC by greater than 50%, and MK571 blocked interstitial
langerhans DC differentiation and maturation, assessed by a decreased expression of the cell
surface markers

CD14, CD1a, CD1c, langerin,CD40, CD54, CD86, CD86, and HLA-DR
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(human MHC class II) (van de Ven, de Jong et al. 2006). DC were exposed to LPS and either
MK571 or Sildenafil, and incubated over night. Cells were again assayed for IL-12 production
and expression of the DC differentiation marker CD11c and the activation markers MHCII,
CD54, CD80 and CD86. Control DC treated with MK571 were severely impaired in their ability
to produce IL-12; this was comparable to the data in the literature.

Inhibition of Mrp4 also

impeded the production of IL-12 from controls cells, although not as severely. Interestingly
activated Mrp1-/- cells produce IL-12 levels similar to the control cells exposed to MK571.
MK571 and Siledafil reduced the production of IL-12 further in Mrp1-/- cells compared to wild
type cells. Global transporter inhibition in the wild type cells reduced IL-12 production to a
greater extent than by just blocking Mrp4 alone. Conversely, in the Mrp1-/- cells blocking all of
the transporters with MK571 reduced IL-12 production to the same extent as did inhibiting just
Mrp4. This would appear to suggest that both Mrp1 and Mrp4 are required for optimum IL-12
production in activated DC. Taking into consideration that MK571 had a similar effect on
control and Mrp1-/- cells, when the cells were examined to determine Mrp4’s role, they were
treated with the Mrp4 inhibitor. In all of the populations; control, treated and untreated, and
Mrp1-/- treated and untreated ~80% of cells expressed CD11c, at equivalent intensity. The loss
of Mrp1 or Mrp4 did not prevent BM-cells from maturing into the DC lineage. However, when
treated with MK571 immature interstitial langerhans cells showed decreased expression of the
activation markers, however only CD1a, CD1c and langerin markers were significantly reduced
(van de Ven, de Jong et al. 2006). Inhibiting either Mrp1 or Mrp4 may not prevent BM cells
from maturing to DC; however it may impede their ability to become fully activated upon
stimulation. This proved to be the case as inhibiting Mrp4 during maturation lead to a dramatic
shift down in the percentages of cells expressing the activation markers MCH II, CD54, CD80,
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and CD86 in wild type cells cells exposed to Sildenafil compared to untreated wildtype cells
activated with LPS. Additionally there was lower activation marker expression in the untreated
Mrp1-/- cells compared to untreated wildtype cells post activation. In the knock out cells treated
with Sildenafil only the percentage of cells expressing CD54 was significantly decreased
compared to untreated knock cells, CD86 expressing cells were lower but was not significant due
to variability.. In terms of which transporter is more critical for DC maturation the data is
inconclusive. That is to say the loss of Mrp1 had the same effect on the percentage cells that
unregulated their activation markers as wildype cells treated with the Mrp4 inhibitor Sildenafil.
Additionally when inhibiting Mrp4 in the knock cells the only the percentage of cells expressing
CD54 was reduced. When mean intensities were examined, the number of activation markers
expressed per cell, the only significant difference was in CD54 expression on the knockout cells.
This is contrast to the previous work, which showed decreases in intensity in MHC II, CD 54,
and CD86 when cells were exposed to MK571. That was however done in human derived DCs,
and data in the literature suggest there may be a species differences in MRP requirements (van de
Ven, de Jong et al. 2006; van de Ven, de Groot et al. 2009). Taken in its entirety this suggests
that both Mrp1 and Mrp4 play a role in DC maturation and activation.
The ultimate test of DC maturation and activation is on the ability of DC to activate T
cells and induce an adaptive immune response. We assayed the ability of DC to activate T cells
in the presence of either MK571, or sildenafil. We discovered the same trend as above, compared
to wildtype cells, the knock out cells were significantly less proficient at activating T cells. As
well cells treated with MK571, the global inhibitor, were equally poor T cell activators compared
to untreated wildtype cells.
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The next phase was to try and elicit the mechanism by which transporters affect DC function.
All of the immune related functions determined to date are effluxed from cells and have either
autocrine or paracrine activity, these include both leukotrines and prostiaglands (Robbiani,
Finch et al. 2000; Legler, Krause et al. 2006; Rius, Hummel-Eisenbeiss et al. 2008). Previous
work proved established that the addition of exogenous leukotriene was able to rescued DC
migration in cells in which Mrp1 was inhabited (Robbiani, Finch et al. 2000). Alone this lines
we decided to try and recue DC maturation by adding the media from untreated control cells.
When media from control cells, even with the addition of MK571, replaced the media in the
treated cells, there was a significant increase in the expression of surface activation makers on
the treated cells. However when we looked at the percentage of cells fully maturing to DC, there
fewer cells expressing the DC maturation marker CD11c. It appeared that addition of exogenous
media was able to increase activation marker expression on cells that matured to DC, but it was
not able to increase the percentage of cells that matured to DC. This may be due to the 2 day lag
time in maturation. The rescue cells did not receive control media for 2 days, this may have
stalled any of the cells in the CD11c low and medium populations in an immature state. The
addition of any potential maturation factors in the control media was unable to push them
forward, pushing only the CD11c high population to full maturation. This may be corrected by
staring the control cells used for the rescue media 2 days ahead of the reaming cultures, this
would allow the rescue cells exposure to the control media and any beneficial factors from day
zero.
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4.5 Conclusion
In contrast to previous studies, that questioned the potential role of Mrp1 and/or Mrp4 in
DC maturation/activation we have demonstrated that the transporters play a pivotal role. In the
previous studies however only one transporter was examined, save the first study which
unintentionally, thought only Mrp1 was being inhibited. In that case inhibitor used MK571, has
inhibitory an effect on most of the Mrps, and they also saw alterations in DC differentiation. We
therefore looked at the possibility that both Mrp1 and Mrp4 play a role in DC function. Our work
shows that indeed both Mrps are required for appropriate dendritic cell maturation and
activation. They appear to have overlapping function or there is a compensatory effect in the
event one is lost. The attempt to determine if there is an autocrine molecule being pumped out to
aid in maturation was however inconclusive. The role of Mrps in DC function requires further
study including endeavoring to discern the molecules that may be involved in the maturation and
activation process.
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Figure Legend.

Figure 4.2 PCR analysis of transporter mRNA expression.
Detection of Mrps in mature and activated mouse BM-dendtric cells. PCR amplification on reverse
transcribed total DC mRNA using primers for Mrp1, Mrp2, Mrp3, Mrp4, and Mrp5. The data is one of
three represented experiments.

Figure 4.3 The loss of Mrp1 and Mrp4 during DC activation reduces IL-12 production but
does not alter activation marker expression.
A. IL-12 production measured by ELISA, by cells activated with LPS, 10 ug/ml, either media alone,
DMSO control, LPS control, MK571 25 uM, and Sildenafil 20 uM. Data is expressed as the mean ±
SEM of duplicate samples. B. Up regulation of activation markers CD54 and CD86 measured by flow
cytometry. Data expressed as mean intensity ± SEM of duplicate samples. Statistical difference (*)
determined using 2-way ANOVA, plus post-hoc test (p< 0.05). Data is one of three representative
experiments.
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Figure 4.4 The loss of function attenuates IL12 production from DCs derived from wild
type and Mrp1-/- mice.
A. IL 12 production with inhibitors adds during DC maturation. LPS control, media, MK571, 25 uM,
sildenafil, 20 uM. Data expressed as ng/ml in supernatant. B. Comparing IL12 produced by wild type and
Mrp1-/- DCs to their respective LPS controls. Data expressed as a percent of control. Statistical difference
( α=control media to ko media, *** wild type to wild type, # ko to ko), determined using 2-way ANOVE,
plus post hoc test (p< 0.05)

Figure 4.5 Inhibition of Mrp function during DC maturation alters cell phenotype.A. Flow
cytometer measure of the % of wild type cells expressing CD11c, MHC, CD54, CD80, and CD86. B. The
% of Mpr1-/- DC expressing CD11c, MHC, CD54, CD80, and CD86. C. Comparison of wild type to
Mrp1-/- DCs expression of activation markers. Statistical difference determined using 2-way ANOVE,
plus post hoc test (* p< 0.05, p< 0.01, p< 0.001)

Figue 4.6 The Mrp4 inhibitor Sidenafil down regulates DC activation markers CD54 in
Mrp1-/- mice.
Flow cytometery measure of DC activation markers on wild type DC and Mrp1-/- DC in media alone or
treated with Sildenafil 20 uM. Data expressed as mean intensity. Statistical differences determined using
2-way ANOVE, plus post hoc test (* p< 0.05)

Figure 4.7 The loss of Mrps 1 and 4 reduces BM- DC ability to activate allogenic T cells.
A. T cell proliferation measured by tritiated thymidine incorporation post activation by wild type or
Mrp1-/- DCs either matured in media alone, or in the presence of either MK571( 25uM) or Sildenafil
(20uM). B. Allogeneic T cell proliferation in response to wild type and Mrp1-/- BM-DC compared to wild
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type Con A control (BM-DC to T cell ration = 1:4). Data expressed as the mean ± SEM of duplicate
wells. Statistical differences determined using 2-way ANOVE, plus post hoc test (*p< 0.05, **p<0.01,
*** p<0.001).

Figure 4.8 Rescue of activation marker up regulation on activated DCs, but not the
percentage of cells displaying CD11c phenotype.
A. Percentage of cells expressing CD11c was decreased when matured in the presence of MK571,
measured by flow cytometery. Data expressed as percent of control cells. B. Upregulation of activation
markers CD54, CD80 and CD86, measured by flow cytometery in rescued cells. Data expressed as mean
intensity. Statistical differences determined using 2-way ANOVE, plus post hoc test (*p< 0.05)
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Table1. Percentage of CD11c cells expressing DC activation markers.
Marker
MHC
MHC+ Sil
CD54
CD54 + Sil
CD 80
CD 80 + Sil
CD 86
CD86 + Sil

FVB
64.25
48.68
49.90
29.93
42.92
24.22
36.24
21.93

FVB/Mrp1-/45.07
43.34
33.32
4.18
27.16
27.27
22.80
13.63

Difference
-19.17
-5.31
-16.56 *
-25.75 **
-15.76 *
3.05
-13.44 **
-8.29

*P < 0.005, **P < 0.001
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Chapter 5: Extended discussion and Future directions

5.1 Discussion
Cancer is still a major health concern in the US, with an estimated 1,479,350 new cases in 2009
and an estimated 562,340 deaths (American Cancer Society, 2010). Cancer is the second leading
cause of death in the United State averaging 599,888 deaths per year; only heart disease has a
higher mortality rate with 631,636 deaths per year (CDC, 2010). From 1975 to 1990, there was
an overall annual 0.5 percent increase in cancer mortalities, however, in the 1990s, the overall 5
year mortality rates began to began to fall. From 1990-1993, there was an overall 0.3 percent
decrease in mortality, from 1993-2001 a 1.1 percent decrease, and from 2001-2006, a 1.6 percent
decline in mortality (NCL, SEER, 2010). This decrease in mortality and subsequent increase in
5 year survival is in all probability due to advances in treatment and early detection. Although
overall mortality rates have dropped, depending on the site of the primary neoplasm, the outlook
is still for the patient may still be grim. Whereas 5 year survival rates for cancers of the testes
and thyroid are above 90%, liver and pancreatic cancers’ 5 year survival rates are 6% and 5%
percent respectively (NIH, 2010).
The ultimate cause of refractory diseases in patients is due to the failure of chemotherapy. Even
today, advances in chemotherapy progress at a sluggish pace.

Statistical increases in

chemotherapy efficacy are measured in terms of months. In a clinical trial comparing secondary
treatments for prostate cancer with Cabaitaxel and mitoxantrone, after primary docetaxel
treatment failure, there was a statistically significant median survival increase from 12.7 months
to 15.1 months (Sartor et al, 2010). Although there was a statistically significant increase in in
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median survival with the addition of the secondary treatment, few people would consider living
an average 2.5 months longer in addition to suffering from the deleterious side effects of
chemotherapy a significant improvement. As traditional chemotherapy agents indiscriminately
kill healthy cells as well as cancer cells, and many new therapies are still taking this approach,
most cancer patients have to suffer through the toxic side effects of chemotherapy.

An

alternative approach to standard chemotherapy treatment has been to overcome drug transporter
mediated resistance, rather than trying to increase the innate toxicity of the chemotherapy agents.
Inhibiting the activity of the efflux transporter responsible for extruding the chemotherapy agent,
would thereby increase the intercellular retention time and cytotoxicity.
The quest to find a clinically effective MDR reversing agent has been ongoing for the past thirty
years. The first ATP transporter to be characterized was P-glycoprotein (PgP) in 1979, and
shortly thereafter, in 1981, the first attempt to use a drug as a PgP inhibitor was verapamil
(Juliana and Lang, 1976, Tsuruo et al, 1981). This re-sensitized vincristine resistant leukemia
cells (Tsuruo et al, 1981). In 1986, the immunosuppressant drug cyclosporine A was shown to
reverse resistance to vincristine and daunorubicin in human T-cell lymphatic leukemia
(Twentyman et al, 1987). Both verapamil and cyclosporine A were tested in clinical trials in an
attempt to reverse MDR in patients. Unfortunately, neither of the compounds was able to
clinically reverse MDR at the highest tolerable dosages (Wu et al, 2008). The reoccurring theme
in all of the first generation inhibitors was low efficacy and high toxicity at clinical doses.
Challenges arose with the search for second, third, and fourth generation drugs showing low
toxicity and higher efficacy, as two additional families of ATP dependent transporters were
discovered. In 1992, the first member of the second family of ATP dependent transporters,
MRP1 was discovered and subsequently the newest ATP family member, breast cancer
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resistance protein (BCRP) was discovered in 1998 (Cole et al, 1992, Doyle et al, 1998). The first
MRP1 inhibitor discovered was the leukotriene LTD4 antagonist MK571, developed in 1995 and
in 1998 the fungal toxin fumitremorgin C was found to inhibit BCRP, thus beginning the race to
find an inhibitor that could be used in the treatment of cancers that overexpressed these
transporters (Gekeler et al, 1995, Rabindran et al, 1998). The challenge to date has been the
synthesis of new compounds that are able to inhibit the growing array of drug resistance
transporters but in addition have low toxicity. Currently, there have been greater than 100
compounds evaluated for the potential to inhibit transporter function (Choi, 2005). One question
that still remains to be resolved is whether to inhibit a particular transporter with a single pump
inhibitor or apply the use of a multi-pump compound to inhibit 2 or more transporters. The
former would probably have fewer side effects, but may be less effective. This decision would
depend on the phenotype of the tumor and the number and type of transporters being over
expressed.
Either strategy has its own potential pitfalls. As we have shown in chapter two, inhibiting Mrp1
alone resulted in several unforeseen consequences and could be a double-edged sword in some
tissues. The major P450s involved in vincristine phase I metabolism are CYP3A4 and CYP3A5
(Dennison et al, 2006). We found the loss of Mrp1 leads to increased Cyp3A4 activity in the
mouse kidney. This increased activity may diminish the effectiveness of vincristine in treating
renal tumors due to increased phase I metabolism of vincristine. Conversely, we also established
a decrease in renal Mrp2 expression, resulting in a buildup of vincristine in the Mrp1 -/- mouse
kidney, which may in turn exaggerate potential renal damage as a result of the chemotherapy.
Mice lacking Mrp1 have been shown to have increased chemotherapy related damage to the
seminiferous tubules, possibly leading to lower fertility (Wijnhold et al, 1998).
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As

chemotherapy alone can render males infertile, combining chemotherapy with an MRP1 or
global MRP inhibitor if any of the drugs in the treatment régime were MRP1 substrates, the
resulting damage would almost certainly cause male infertility (Drasga et al, 1983).
Although the effects described above as a result of inhibiting drug transporters to increase the
efficacy of chemotherapy treatment are deleterious, anticancer therapy is usually relatively short
in duration and the patient may thereby be spared any permanent damage. However MRP1,
MRP4, and MRP5 are known to transport antiviral therapeutics as well as anticancer
chemotherapy drugs (Fridland et al, 2000). HIV infection has been shown to increase the
expression of MRP1, MRP4, and MRP5 in infected cells which translates into a reduction in the
intracellular concentration of the antiviral cocktail.

When trying to circumvent viral drug

resistance, inhibiting the transporters may appear as a viable addition to highly active
antiretroviral therapy (HAART), in HIV patients however, the result may again be unwanted side
effects. As we illustrated in Chapter 3, Mrp1-/- mice have decreased levels of circulating
testosterone.

Long term MRP1 inhibition in a clinical setting may lead to chronic low

testosterone, manifesting in decreased fertility and sex drive, depression, obesity, diabetes,
cardiovascular diseases and possibly osteoporosis (Hoffman, 2008). Furthermore the long term
inhibition of MRP1 and the resulting changes in steroid levels and ensuing alterations in
metabolizing enzymes may have unforeseen systemic physiological and pharmacological
consequences.

The steroid related induction of Cyp3A4 in the kidney may potentiate the

bioactivation of aflatoxin B1, an Mrp1 substrate, resulting in increased nephrotoxicity and an
increased risk of renal carcinoma (Mathuria and Verma, 2008). Also, the widely used drug
acetaminophen (APAP) can undergo Cyp3A4 bioactivation with the potential buildup of toxic
metabolites resulting in severe APAP induce renal damage (Ma et al, 2009).
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The long term inhibition of MRP1 in conjunction with antiviral therapy may not be a viable
choice due to, but not limited to, the above unfavorable effects. Even the short term inhibition of
MRP1 during chemotherapy may result in more serious side effects than just increased toxicity.
As we discovered in chapter 4, both MRP1 and MRP4 have been implicated in DC maturation
and activation. Within 24 hours from the time a DC acquires and processes a pathogenic
antigen, it has gone through maturation and migration to a draining lymph node (He et al, 2006).
If a patient were undergoing chemotherapy with an MRP1, MRP4 or a global MRP inhibitor, and
were to be exposed to a unique pathogen, the resulting attenuation in DC activation would lead
to a delay in the adaptive immune response. This, when added to an already crippled immune
system due to the chemotherapy, could overwhelm the innate immune response resulting in
increased morbidity or mortality. In this scenario, even a normally nonpathogenic organism
could cause a potentially fatal infection.
In conclusion, reversal or prevention of ABC transporter mediated MDR in cancer patients
undergoing chemotherapy is still the Holy Grail in clinical oncology. Prevention of the MDR
phenotype would greatly increase the efficacy of existing chemotherapy drugs, potentiate therapy
in intrinsically resistant cancers, and potentially eliminate refractory disease in cancer patients.
Research is continuing with both known and newly synthesized compounds in an attempt
develop an effective transporter inhibitor. There have been some promising in vivo and clinical
successes, including verapamil, cyclosporine A, or PSC833 when administration prior to treating
MDR resistant tumors in mice with the chemotherapy drug doxorubicin. Pretreatment increased
doxorubicin accumulation in tumor cells from 68% to 94% (Shen et al, 2007). However, data
found in the literature reports that the severe side effects caused by therapeutic levels of
traditional transporter inhibitors greatly would hamper any viable clinical application. This
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study reports potentially negative physiological consequences resulting from global transporter
inhibition.

There is, however, some promising research being done with

nontraditional

transporter inhibitors especially with RNA interference technologies, including short hairpin
RNA (shRNA),and small interfering RNAs (siRNA) (Lage H , 2008). One such technology with
promising results is StealthTM RNAi, which targeted Pgp (Xiao et al, 2008). The administration
of Stealth RNAi in conjunction with the chemotherapy drug, Navelbine, increased the drug
efficacy 9 fold (Xio et al, 2008). The advantage to these innovative treatments is they can be
targeted to the tumor cells and have little, if any, affect on surrounding tissues.
Reversing the MDR phenotype is still a viable strategy in the treatment of drug resistant
neoplasms. With the advent of tumor targeted therapies and the reduction of collateral damage
to surrounding tissues and deleterious side effects, there is a light at the end of the tunnel in
search for effective and safe anti cancer therapies.

5.2 Future Directions
Our preliminary data suggest that Mrp1 and/or Mrp4 are required for effective DC maturation
and activation. The loss of either of the transporters negatively impacted the DC ability to
properly mature and upon stimulation to be become efficiently activated. It appears thus far that
both transporters play some role in DC function. We would like to continue using the Mrp1-/mouse model to fully characterize the roles Mrp1 and Mrp4.play in DC function. Additionally
our data shows that there is an as of yet undetermined MRP substrate that has been implicated in
DC maturation/activation. Our data indicates that there is a compound that is exported out of the
cell as the DC goes through maturation and activation. We would like to confirm this hypothesis,
and confirm the existence of and characterize of the compound. If the existence of the MRP
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substrate can be determined this may provide immunologist with a new tool for manipulating the
immune response.
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